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Bone marrow contains many cell types including hematopoietic cells and their 
precursors, adipocytes, endothelial cells, and osteocytes.  There are also cells with 
reported capacity to differentiate into bone, cartilage, and other tissues.  Their 
descriptive terminology varies and includes mesenchymal stem cell (MSC), stromal 
stem cell (SSC), and mesenchymal progenitor cell (MPC), used herein.  The cell-
surface phenotypes of cultured MPCs have been described for humans and other 
species.  However, there is no consensus on their phenotype from uncultured bone 
marrow mononuclear cells (BMMNC) and poor understanding of their phenotypic 
changes during culture.  These issues complicate clinical use of MPCs in cell-based 
therapies as extended periods of culture (typically 4-6 weeks) are required to purify 
and expand cell numbers, making the original phenotype unclear and delaying 
treatment.  To address this problem, my experiments were designed to study the 
phenotypic changes that occur in equine BMMNCs from isolation through one month 
culture.  Flow cytometry and reverse transcriptase quantitative polymerase chain 
reaction (RT-qPCR) were used to analyze cell-surface molecules.  Results 
demonstrated numerous dynamic changes in BMMNC phenotype.  Next, cell sorting 
experiments were performed to determine if phenotypic changes during early culture 
could be exploited for MPC colony enrichment.  Magnetic activated cell sorting 
(MACS) was used to separate adherent BMMNCs based on their expression of cluster 
of differentiation (CD) marker CD14.  BMMNCs were separated into three groups; 
CD14 positive, CD14 negative, or unsorted.  Flow cytometry and RT-qPCR were used 
 to evaluate sorting efficiency and compare groups over time.  At day seven, cells 
positively selected for CD14 were significantly more likely to form colonies than both 
unsorted and negatively selected cells (P≤0.005).  Further, MPCs maintained low 
levels of CD14 expression in long-term culture and upregulated expression in response 
to lipopolysaccharide.  These findings were surprising because by definition, MPCs 
are thought to be non-hematopoietic because they lack expression of specific 
hematopoietic molecules such as CD14.  Only certain lineages of hematopoietic cells 
are known to express CD14.  Results of my studies support that equine MPCs express 
and are enriched by CD14, suggesting they have either been misclassified, or may 
represent a differentiated descendant of a hematopoietic cell.   
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CHAPTER 1 
GENERAL INTRODUCTION 
 
Broad Objectives of Dissertation Research 
 Bone marrow is composed of many cell types.  My research involved a 
particular subset of bone marrow cells known as mesenchymal progenitor cells 
(MPC).  The MPCs of humans and other species have been studied for approximately 
forty years.  Despite decades of MPC research, these cells are still relatively poorly 
understood compared to other well-defined bone marrow populations, such as 
hematopoietic stem cells (HSC).  My overall objective was to gain a better 
understanding of what unique cell surface properties these putative MPCs possess.  
Long-term goals for my research are to identify candidate MPC surface markers to 
facilitate isolation of MPCs in future cell sorting studies and to evaluate the clinical 
usefulness of sorted MPCs in cell-grafting procedures.   The horse was chosen as a 
model organism to supply large quantities of bone marrow cells from each aspirate, 
thereby facilitating multiple analyses of each sample. 
The first objective of my research was to characterize the cell surface 
phenotype of putative equine MPCs derived from bone marrow.  I was interested in 
how the cell surface markers changed over time in culture as the MPC population was 
established.   My hypothesis was that the cell surface phenotype of bone marrow 
derived MPCs would be dynamic from cell isolation through one month culture.   
Results of my initial study demonstrated a number of changes in cell surface 
molecules during establishment of MPC cultures, confirming the hypothesis.  
 Contamination with adherent hematopoietic cells, such as monocytes and their 
descendants, creates a substantial obstacle to obtaining relatively pure MPC cultures 
for analysis.  One way to reduce the level of hematopoietic cell contamination is to 
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sort bone marrow cells based on a cell surface protein that is differentially expressed 
between the populations.  According to the accepted classification of human MPCs, 
the CD14 cell surface protein, also known as the lipopolysaccharide receptor (LPS-R), 
should be differentially expressed between MPCs and adherent hematopoietic cells.  
This protein should be present on the cell surface of monocytes, macrophages, and 
dendritic cells.  According to the literature, it should not be detectable on the surface 
of MPCs.  Therefore, my second hypothesis was that MPC colony formation would be 
enriched in the CD14 negative fraction of adherent, cultured bone marrow cells when 
separated from the CD14 positive hematopoietic fraction.  Results of the second study 
did not confirm the hypothesis.  In fact, the data indicated just the opposite; MPC 
colony formation was enriched in the CD14 positive fraction. 
  In the horse, my data suggested that putative MPCs came from a CD14 
positive cell population.  Based on current knowledge, that implies equine MPCs are 
descendants of a hematopoietic cell, or MPCs have previously been misclassified.  
This finding has important implications in the clinical application of MPCs in cell 
grafting procedures.  If the goal for cell-based therapies is stromal tissue regeneration, 
putative MPCs do not appear to be a cell type capable of achieving this goal in vivo, 
despite their behavior during in vitro cell differentiation studies.  If the goal for 
clinical application putative MPCs is to improve tissue healing, without the absolute 
need for “tissue regeneration”, they may play an important role in cell-based therapies.  
The current literature suggests the latter goal is attainable, realistic, and a useful 
indication for MPCs clinically.   
 The following chapters expand upon the information contained in each of the 
above paragraphs.  The remainder of this chapter focuses on important background 
information related to the field of MPC biology and bone marrow analysis.  The 
second chapter describes the dynamic changes early in culture of bone marrow 
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aspirate during the establishment of the MPC population.  The focus of the third 
chapter is the enrichment of MPC colony formation using the cell surface molecule 
CD14 to separate hematopoietic and putative stromal cell lineages.  The final chapter 
summarizes the implications for clinical application of putative MPCs in cell grafting 
procedures. 
 
History of Bone Marrow Research  
Bone marrow cytological analysis was an innovative technique developed over 
150 years ago to improve our understanding of the highly complex bone marrow tissue 
compartment.  Morphology of bone marrow cells was first described by E. Neumann 
in 1868 [1].  Later, he described the transformation of “fatty marrow” into functional, 
red hematopoietic tissue in conditions of severe anemia.  In the early twentieth 
century, Alexander A. Maximow was credited for confirming the Unitarian Theory of 
Hematopoiesis: that all blood cells arise from a common precursor [2].  Combined, 
these observations led to the important advances in the field of bone marrow 
evaluation, including the diagnosis and treatment of neoplasias such as leukemia, 
aplastic anemia from radiation sickness, and in infections such as tuberculosis [3].    
Over the history of bone marrow research, techniques were developed to 
harvest samples from living patients in order to acquire bone marrow cells for 
cytological analyses.  Pianese first attempted to obtain a diagnostic sample of bone 
marrow in 1903 via trephination of the femoral epiphysis to study hematologic 
conditions [1].  The first description of a sternal bone marrow aspirate was by C. 
Seyfarth in 1922 using a “puncture needle” [1].  In 1971, a new type of trephine 
needle was patented by Khosrow Jamshidi [4] which allowed for bone marrow tissue 
to enter the lumen of the needle without being crushed.  Presently, there are many 
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different types of commercially available bone marrow aspirate needles; however 
most incorporate the cannula and stylet design developed by Jamshidi.   
In the 1950’s through 1970’s, a team led by Edward Donnall Thomas at the 
Fred Hutchinson Cancer Research Center, pioneered work in the field of 
hematopoietic stem cell transplantation following bone marrow ablation [5, 6].  In 
1990, Thomas received a Nobel Prize for his work on graft versus host disease in bone 
marrow transplantation.  The first successful human bone marrow transplantation was 
performed by Robert A. Good in 1968 at the University of Minnesota to treat a boy 
with a severe sex-linked immunodeficiency [7].  Worldwide, about 30,000 autologous 
(donor is the recipient) and 15,000 allogenic (donor is a member of the same species, 
but is not the recipient) bone marrow transplants are performed annually in the 
treatment of a variety of diseases [8]. 
Bone marrow aspirate can be obtained from several anatomic sites.  The most 
common site for bone marrow aspiration in people is the posterior iliac crest of the 
pelvis.  This site provides a rich source of red marrow.  Other less frequently utilized 
sites for aspiration of bone marrow in humans include the anterior iliac crest, 
sternabrae, proximal humerus, and the anteromedial surface of the tibia in young 
children.   The anterior iliac crest is generally used only in patients who are obese, 
since their large body size makes the posterior iliac crest inaccessible.  The sternabrae 
carries a small risk of inadvertent lung or cardiac puncture, leading to safety concerns, 
and therefore, less frequent usage in people.  Finally, the marrow space in the 
proximal humerus and anteromedial tibia fill with yellow marrow with age, making 
them unsuitable donor sites in the adult. 
Several anatomic sites are also used in horses for collection of bone marrow 
aspirate.  The sternabrae are commonly used for bone marrow aspiration in the 
standing, sedated horse.  Another frequent site utilized in the horse is the tuber coxae 
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of the pelvis.  In addition to bone marrow aspiration, both of these sites are also 
important locations for acquisition of cancellous bone graft.  A rarely reported site 
which has been used for bone marrow aspiration in young horses is the tibia [9].   The 
humerus has not been reported as an aspiration site in horses, although the region has 
been utilized in other species [10-13]. 
 
History of Mesenchymal Progenitor Research 
In the 1970s, A.J. Friedenstein published a series of papers on the clonal nature 
of bone marrow stromal cells which initiated the field of bone marrow-derived 
mesenchymal progenitor cell (MPC) research [14, 15].  In 1999, M.F. Pittenger used 
flow cytometry to characterize the cell surface proteins expressed on cultured MPCs.  
He also demonstrated the capacity of MPCs in vitro to differentiate into cells of 
osteogenic, chondrogenic, and adipose lineages [16].  Since that time, well over 
10,000 articles related to MPCs have been published.  In spite of all of the research 
and interest in MPCs, there is still a great deal of controversy on the exact definition, 
characteristics, and therapeutic uses of MPCs.  Basic guidelines have been established 
by the International Society for Cellular Therapy (ISCT) for the minimal criteria to 
define human Multipotent Mesenchymal Stromal Cells (MSC), including clarification 
of nomenclature [17].  According to the ISCT, the plastic-adherent cells isolated from 
bone marrow and other sources do not meet the generally accepted criteria for stem 
cell function, rendering the terminology mesenchymal stem cell inaccurate and 
potentially misleading to the public.  Further, since MSC can be interpreted as either 
mesenchymal stem cell or mesenchymal stromal cell if not clearly defined, herein the 
more general term, mesenchymal progenitor cell (MPC) will be used when referring to 
this cell type.  Besides adherence to tissue culture-plastic, according to the ISCT 
definition, humans MPCs must express the cluster of differentiation (CD) molecules 
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CD105, CD73, and CD90 and lack expression of CD45, CD34, CD14 or CD11b, 
CD79alpha or CD19, and HLA-DR  molecules on their cell surface [18].  
The cluster of differentiation (CD) molecule nomenclature classifies 
monoclonal antibodies by the epitope they recognize on the cell surface [19, 20].  If 
two or more specific monoclonal antibodies bind to the molecule of interest, a CD 
designation is assigned.  If only one monoclonal antibody binds, a provisional 
indicator, “w” is included in the name.  To date, more than 350 designations have been 
classified for humans.  Although the CD classification system was initially developed 
for leukocytes, a number of other cell types, including stromal cells, have been 
phenotyped based on the presence or absence of CD molecules [21].  The 
classification of human MPCs using the CD phenotype has attempted to standardize 
the definition of MPCs using more objective criteria than simple plastic adherence. 
In addition to cell surface properties, ISCT guidelines indicate that human 
MPCs must differentiate to osteoblasts, adipocytes, and chondroblasts in vitro [18].  
Criteria used to define in vitro differentiation vary by desired tissue and include 
histochemical staining results, gene expression data, and chemical properties.  For 
osteogenic differentiation, intracellular calcium/protein ratios can be used to 
demonstrate calcium accumulation in treated cells.  Alkaline phosphatase (ALP) and 
alizarin red dyes are commonly used to stain for bone (ALP is a by-product of 
osteoblastic activity) and mineral (alizarin red stains calcium) deposition.  Increased 
levels of expression of genes such as osteonectin and osteocalcin can also be used to 
provide evidence of osteogenic differentiation.  For adipogenic induction, histological 
staining with Sudan black or Oil Red O is frequently used to assess lipid 
accumulation.  Antibody staining for leptin, a hormone produced by adipocytes, can 
also be used to confirm adipocytes are functional [22].  Increased expression levels of 
genes such as peroxisome proliferator-activated receptor- γ (PPAR-γ) and fatty acid 
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binding protein 4 (FABP4) also provide supporting evidence of adipogenesis.  
Chondrogenesis can be evaluated via immunohistochemical staining by comparing 
levels of collagen staining (e.g. collagen type II staining provides supporting evidence 
of chondrogenesis, type X suggests hypertrophic cartilage,  and other collagens such 
as types I and III suggest fibrous tissue formation).  Other stains such as Safranin 
O/fast green and Toluidine blue can be used to assess matrix metachromasia, which is 
indicative of glycosaminoglycan synthesis.  Gene expression levels of the various 
collagen types and matrix components such as aggrecan provide additional support of 
chondrogenesis.   
Putative MPCs have been isolated from a variety of human tissue sources 
including bone marrow, umbilical cord blood, adipose tissue, peripheral blood, 
muscle, periodontal tissue and periosteum.  Bone marrow has been the most studied 
and utilized source of MPCs to date in people.  Therefore, my research has focused 
primarily on equine MPCs acquired from bone marrow aspirates. 
 
Anatomy of Bone Marrow 
Bone marrow is found in the medullary cavities of bones and contains a 
heterogeneous mixture of cells including hematopoietic cells and their precursors, 
adipocytes, endothelial cells, fibroblasts, and bone cells such as osteoblasts and 
osteoclasts.  Bone marrow can be classified as either yellow (containing primarily 
adipocytes) or red (containing mainly hematopoietic cells).  Neonatal human bone 
marrow is exclusively red marrow and remains as such for about seven years.  With 
aging, bone marrow becomes more of the yellow form unless a stimulatory event, such 
as severe blood loss, causes it to convert back to red marrow.  In adults, red marrow is 
found primarily in the end of long bones, near the hip, in the sternabrae, vertebrae, ribs 
and skull.  Red and yellow bone marrow spaces are found in similar anatomic 
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locations in the horse.  Rich sources of red marrow in the horse include the sternabrae 
as shown in Figure 1.1. 
 
 
  
 
 
 
 
 
 
 
Figure 1.1 Cross section of an equine sternum (A) revealing seven large marrow 
cavities that can be accessed to obtain bone marrow aspirate.  An enlarged photograph 
of the third marrow element (B) further depicts the rich reservoir of bone marrow. 
 
Red bone marrow is highly vascular and contains fibrous networks of cells, 
blood vessels, bone, and fibrous tissue.  The stroma provides a microenvironment, or 
niche, to facilitate and regulate the parenchymal cells which carry out hematopoiesis.  
Hematopoietic stem cells give rise to leukocytes (white blood cells), erythrocytes (red 
blood cells), and thrombocytes (platelets).  Immature blood cells are normally blocked 
from leaving the marrow because they lack cell surface adhesion proteins necessary 
for diapedesis.  Other stem cells found in the marrow include endothelial stem cells 
which give rise to blood vessels and MPCs which give rise to cells such as adipocytes, 
chondroblasts, and osteoblasts in vitro.   
 
 B 
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The Horse as a Model Organism 
Expanded knowledge of the behavior of MPCs in nonhuman biomedical 
research animal models both in vitro and in vivo is an important step for future 
application of these cells in human or animal patients.   The horse is a good candidate 
for MPC research due to its size (which allows for relatively large sample collections).  
Further, horses are a well developed model system to test therapeutic applications in 
cartilage, tendon, and bone healing, facilitating the application of MPC preparations to 
in vivo testing. The horse has a distinct advantage as a model organism for MPC 
studies as multiple tissues can be sampled using minimally invasive techniques, under 
light sedation and local anesthesia.  Autologous grafting procedures are possible 
because MPCs can be collected non-lethally from the same horse, eliminating the 
potential confounding factors of transplanting allografts into immunocompetent 
recipients.  Putative MPCs have been isolated from a variety of equine tissues 
including bone marrow, umbilical cord blood, peripheral blood, adipose tissue, and 
muscle [23-29].   
The horse has been a long standing model for osteoarthritis research. The first 
study examining arthritis in the horse was reported over 50 years ago [30]. The equine 
model is well suited for application to human joint disease because of the horse’s 
athletic nature, and the large biomechanical forces which equine joints must withstand.  
In contrast, smaller mammals, such as mice or rabbits, cannot sustain biomechanical 
forces remotely comparable to those measured in human joints.  A publication 
utilizing horse MPCs with measurements of in vivo cartilage repair has become 
available [31].  Numerous additional studies measuring chondrogenic potential of 
equine MPCs in vitro have been reported [25, 32-37].   
Horses are also important models for the study of tendon healing. Studies 
range from the effect of extracorporeal shock wave therapy [38], microcurrent tissue 
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stimulation in vitro [39], to measurement of growth factors and tendon matrix 
components in normal and injured tendons [40-44].  The induction of equine 
superficial digital flexor tendonitis using collagenase injection [40-43, 45, 46] is a 
well-established model which is frequently utilized in the study of MPC application to 
tendon defects.  Since horse tendons experience forces that meet or exceed the 
magnitudes of force experienced during healing of human tendon injuries, the horse is 
a suitable model system for extrapolation to human tendon lesions. 
A model system to evaluate bone healing has been well established for the 
horse.  The metatarsal osteotomy procedure is a minimally invasive way to measure 
bone stability and gap healing [47, 48].  Interestingly, osteogenic cell populations have 
been found to vary at different skeletal sites in the horse [49], emphasizing the need to 
utilize a highly standardized model system.   
 The horse has a number of advantages that make it well suited as a model 
organism for bone marrow research; however some disadvantages are present.   Many 
of the antibody reagents used to isolate human MPCs do not recognize the equine 
form of the respective molecules, leading to challenges in antibody-based isolation 
and analysis of putative equine MPCs.  Further, many of the advanced transgenic 
model systems such as green fluorescent protein (GFP) transgenesis, which can be 
used to track GFP donor cells in non-GFP recipients, cannot be applied to horses.   
 
Current Therapeutic Applications of Mesenchymal Progenitor Cells to Humans  
Putative mesenchymal progenitor cells have been used in a number of studies 
for treatment of a variety of disease conditions.  Most human studies are still in Phase 
1 clinical trials to demonstrate safety in MPC cell-grafting procedures.  While a 
rapidly growing quantity of clinical data supports the safety of mesenchymal stem cell 
transplants, the efficacy data are variable and of mixed benefit [50].  Recent clinical 
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trials tested MPC treatment for a variety of indications including amyotrophic lateral 
sclerosis [51], radiation-induced lung injuries [52], and augmentation to hematopoietic 
stem cell transplants [53].  Unfortunately, these studies do not show a significant 
treatment effect outside of possible immune modulation and anti-inflammatory 
properties.  When bone marrow derived MPCs have been studied for heart disease 
[54], stroke [55], and other neurodegenerative disorders, progress has also been mixed 
and without significant benefit [50].  To date, only one prospective study of human 
MPC transplantation into a cartilage defect has been published [56].  This study found 
no significant clinical improvement in patients who received MPCs compared to their 
cell-free controls, with minor improvements in biopsy histologic scores.  One area 
MPCs have been utilized with apparent signs of positive therapeutic effect is the 
control of graft-versus host disease [57], supporting the concept that MPCs function 
primarily through immune modulation.   
The International Society for Stem Cell Research (ISSCR) has created a series 
of guidelines for responsible translational stem cell research that highlight some of the 
challenges occurring in the clinical application of human MPCs [58].  Specifically, 
ISSCR wants to prevent exploitation of patients’ hopes by preventing “stem cell 
therapies” that lack credible scientific rationale, transparency, oversight, or patient 
protections.  The ISSCR recommends rigorous preclinical testing in animal models 
whenever possible because it is difficult to predict in vivo MPC behavior from in vitro 
studies alone.  They also call on researchers to publish positive results, negative 
results, and adverse events to promote transparency in clinical therapeutic trials.  My 
research adds knowledge to the field of MPC biology using a well accepted model 
organism with the potential for translational impact on a variety of human MPC 
clinical applications. 
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Questions to be Addressed by Dissertation Research 
Bone marrow aspirate contains a heterogeneous mixture of hematopoietic and 
non-hematopoietic cell types that become more homogeneous over the first three 
weeks of culture.  I wanted to develop a better understanding of the temporal changes 
equine bone marrow cells undergo during early culture expansion.  My hypothesis was 
that the cell surface phenotype of bone marrow derived MPCs would be dynamic from 
cell isolation through one month culture.  There are no uniformly accepted definitive 
phenotypes or surface markers that can be used to identify or isolate MPCs from 
native bone marrow aspirate samples [59].  In fresh bone marrow aspirate, cells of 
varying maturity in both hematopoietic and non-hematopoietic lineages are present, 
with varying levels of surface protein expression within each population, making 
separation of cells from distinct lineages difficult.  During early culture, the proportion 
of hematopoietic cells committed to terminal differentiation is reduced via 
spontaneous apoptosis and removal due to non-adherence, leading to a more uniform 
population of mesenchymal cells.  Most studies evaluate MPC cell surface markers 
after expansion in culture in order to obtain sufficient cell numbers for analysis [60-
63].  However, there are conflicting reports of MPC marker protein expression 
patterns when comparing phenotypes of freshly sorted MPCs to expanded MPCs [64, 
65].  These studies suggest that the phenotype of MPCs is dynamic during isolation 
and culture processes.   
The broad aim of the studies in this thesis was to identify some of these early 
changes in cell-surface phenotype.  Long term, these changes might be capitalized on 
for the purpose of improved cell separation.  Chapter 2 describes my preliminary work 
in defining the molecular characteristics during establishment of putative MPC 
cultures.  Chapter 2 also discusses the importance of temporal gene expression 
analysis as a component of the characterization of putative MPCs.  I sought to evaluate 
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dual protein/gene analysis to assess the usefulness of gene expression data in 
confirming negative protein results and accounting for kinetic changes of transcription 
and translation in bone marrow cells during expansion in culture.  Gene expression 
data has been utilized primarily in previous MPC studies to evaluate differentiation 
capacity into terminally differentiated tissues (e.g. collagen type II for cartilage; 
osteonectin for bone) [16, 66].  When monoclonal antibodies are used to 
immunophenotype cells in uncharacterized tissue, gene expression data provides 
supporting evidence for protein expression in the cells and helps to validate the 
reactivity of the antibody.   
An important step in the long-term goal of improved cell separation is 
identification of molecules that are differentially expressed between MPCs and 
hematopoietic cells.  MPCs of humans and other species are reported to lack 
expression of the cluster of differentiation (CD) marker CD14, also known as the 
lipopolysaccharide receptor (LPS-R) on their cell surface [18, 67].  Chapter 3 
describes the analysis of CD14 expression in equine MPCs.  I aimed to evaluate CD14 
expression patterns in equine bone marrow as a potential negative MPC marker.  My 
hypothesis was that MPC colony formation would be enriched in the CD14 negative 
fraction of adherent, cultured bone marrow cells when separated from the CD14 
positive hematopoietic fraction.  Since the CD14 cell surface protein is typically found 
on monocytes and closely related hematopoietic cells, it appeared to be a good 
candidate protein for differential expression between adherent hematopoietic cells and 
putative MPCs.  There are no reports of CD14 gene or protein expression status in 
equine MPCs.  As a preliminary step in this study, I utilized temporal evaluation of 
gene and protein expression to assess the levels of CD14 expression in freshly isolated 
cells through one month of culture.  In fresh marrow, cells of early hematopoietic 
origin did not express CD14 or other hematopoietic specific markers such as 
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CD11a/CD18 uniformly in the expected populations, complicating separation of 
hematopoietic versus non-hematopoietic cells.  It was proposed that many freshly 
isolated bone marrow cells of hematopoietic origin were too immature to express 
specific surface proteins that would allow for distinction between cell lineages.  Based 
on preliminary studies, I determined that short term culture (approximately 2 days) 
allowed adherent cells in culture to reach a stage when they could express CD14 
molecule if that was their lineage commitment (hematopoietic) and be separated with 
relative purity from cells that did not express CD14 (non-hematopoietic).  Utilizing a 
technique called magnetic activated cell sorting (MACS), I expected that lineage 
committed monocytes and neutrophils (which are positive for CD14 expression) could 
be separated from putative MPCs (which are reported to be CD14 negative in other 
species) in bone marrow cultured 2 days using a mouse anti-equine CD14 antibody.  
In contrast to my expected outcome, the anti-equine CD14 antibody concentrated the 
equine MPC colony forming units (CFU) in the CD14 positively selected cells, while 
the CD14 negative fraction of the bone marrow was nearly devoid of CFU, rejecting 
my hypothesis.   
Given the surprising nature of my results, I wanted to press further in the study 
of CD14 expression in MPCs by examining putative MPCs for long term retention of 
CD14 expression.  Over time, I observed a dramatic decrease in CD14 expression by 
the cultured bone marrow cells; however, low levels of expression were detected 
throughout culture.  These results suggest that cells with initial high levels of CD14 
(CD14 positive on MACS separation) are either differentiating into another cell type 
or down-regulating their expression in response to the culture environment.  
In order to determine if the low level of CD14 detection in MPCs was real or 
anomalous, I proposed to stimulate MPCs with lipopolysaccharide (LPS) to see if 
CD14 expression in MPCs would be up-regulated in response.   Established cultures 
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of putative MPCs were tested and found to be LPS responsive, with an increase in 
CD14 gene and protein expression following LPS exposure.  These results suggest 
CD14 cell surface receptors are present and poised for upregulation in MPCs.    
Most characterization studies of culture expanded MPCs in humans and other 
species include use of a proteolytic enzyme called trypsin as part of their cell harvest 
protocols to detach adherent cells prior to flow cytometry analysis.  I aimed to 
determine if damage to the CD14 epitope by trypsin could offer a possible 
explaination for the descrepency between previous MPC characterization studies and 
my findings.  I wanted to test the sensitivity of the equine CD14 surface protein 
receptor to trypsin under typical cell dissociation conditions.  Established cultures of 
MPCs were harvested using either 0.25% trypsin or Accumax® (Innovative Cell 
Technologies Inc. San Diego, CA) cell dissociation solutions.  Flow cytometry results 
showed a significant drop in mean fluorescence intensity detection when trypsin was 
used for cell harvest compared to cells harvested with Accumax®.  In fact, when 
trypsin was used, levels of CD14 were undetectable and had mean fluorescence 
intensity comparable to the negative control antibodies.  Equine CD14 is clearly 
trypsin labile, invalidating flow cytometry data collected following trypsinization.  
This could be a factor in flow cytometry analyses in other species and could be a 
plausible explanation for the discrepancy between my detection of CD14 protein in 
equine MPCs and the negative CD14 expression results reported in other species. 
Only certain lineages of hematopoietic cells (e.g. monocytes, macrophages, 
dendritic cells, and to a lesser extent neutrophils), are known to express CD14.   By 
definition, MPCs of other species are classified as non-hematopoietic in lineage 
because they lack expression of specific hematopoietic molecules such as CD14.  The 
expression of CD14 by equine MPCs supports the concept that these cells arise from a 
hematopoietic lineage precursor and may not be truly “stromal” in origin (if a cell 
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must be CD14 negative to be stromal).  Based on my results, I believe that equine 
MPCs are likely differentiated descendants of a monocytic precursor cell that have 
down regulated their expression of CD14 in response to the culture environment.  It is 
also possible that previous descriptions of MPCs have misclassified these stromal cells 
as CD14 negative, when they should have been classified as low positive for CD14 
expression.  Further studies are needed to elucidate which of the two possibilities is 
true, as cellular lineage has implications for the application of these cells clinically.  If 
MPCs are descendants of hematopoietic cells, can they be expected to form a 
differentiated stromal tissue such as cartilage or muscle in vivo?  What is their 
therapeutic value and what should be the realistic expectations for outcome when 
evaluating their clinical benefits?  If they are a misclassified stromal cell, can CD14 be 
used as a positive selection marker early in culture for enriched isolation of MPCs and 
improve the quality and speed for cell graft preparation?  In future studies I hope to 
address these questions and expand current knowledge of the equine MPC.  The field 
of MPC biology holds great potential to have a significant impact on a host of human 
and animal diseases, but steps need to be taken to ensure transparency and credible 
scientific rationale in their clinical use.  
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Abstract 
Mesenchymal progenitor cells (MPCs) are often characterized using surface 
markers after expansion and treatment in culture.  There are no studies directly 
comparing gene and protein markers in undifferentiated samples during the very early 
phases of culture.  The goal of this study was to evaluate temporal gene and protein 
expression changes during establishment of equine MPC cultures.  Bone marrow 
aspirate was obtained from thirty five horses and processed by density gradient 
centrifugation.  In freshly isolated bone marrow, mononuclear cells had variable 
expression of CD44, CD11a/CD18, CD90 and CD45RB cell surface molecules.  After 
two hours of culture, bone marrow mononuclear cells had a phenotype of CD44hi, 
CD29hi, CD90lo, CD11a/CD18hi and CD45RBlo.  Isolated mononuclear cells were 
analyzed by flow cytometry and RT-qPCR at 2, 7, 14, 21 and 30 days of culture.  At 
all culture time points, gene expression was in agreement with cell surface protein 
expression. In established cultures of MPCs, cells remained robustly positive for 
CD44 and CD29.  The proportion of positive cells and the mean fluorescence intensity 
of positive cells increased for CD90 expression as MPC cultures became more 
homogeneous.  Inversely, the population of cells in culture decreased expression of 
CD11a/CD18 and CD45RB molecules over time.  The decreased expression of the 
latter molecules makes these useful negative markers of established MPC cultures 
under normal expansion conditions.  The results of this study demonstrate numerous 
dynamic changes in cell surface molecule expression during early establishment of 
MPC populations which may aid to improve MPC isolation methods for research or 
therapeutic applications. 
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Introduction 
Mesenchymal progenitor cells (MPC) have been studied extensively in many 
species since the first report by Friedenstein over thirty years ago [1].  
Characterization studies of established human MPC cultures using differentiation 
assays, gene expression analysis, and cell surface protein markers have been 
performed for nearly a decade [2].  Most studies evaluate MPC cell surface markers 
and gene expression after expansion in culture in order to obtain sufficient cell 
numbers for analysis [3-6].  However, there are reports of conflicting results in MPC 
marker protein expression patterns when comparing phenotypes of freshly sorted 
MPCs to expanded MPCs [7, 8].  These studies suggest that the phenotype of MPCs is 
dynamic during isolation and culture processes.      
Temporal changes in cell surface protein expression during expansion in 
culture have been reported in only a few studies.  In the original MPC description by 
Pittenger et al. [2],  population enrichment from day two through fourteen was 
described based on flow cytometric measurement of SH2 and SH3 expression, but full 
cell surface protein characterization was not reported until passage one or two using 
expanded cells.  Another study reported no temporal changes in cell surface phenotype 
for bone marrow cells after they had reached confluence in culture compared to their 
next five passages [9].  Although these studies have added important information 
concerning cell expansion, early immunophenotype changes remain incompletely 
understood.   
The use of gene expression data in most MPC studies has focused primarily on 
assessment of MPC differentiation capacity into terminally differentiated tissues (i.e. 
collagen Type II for cartilage; osteonectin for bone) [2, 10].  When monoclonal 
antibodies are used to immunophenotype cells in a previously uncharacterized tissue 
type, gene expression data provides supporting evidence for protein expression in the 
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tissue and helps to validate the reactivity of the antibody.  The advantage of dual 
protein/gene analysis is to confirm negative protein results and account for kinetic 
changes of transcription and translation. 
Early bone marrow cultures contain a heterogeneous mixture of cell types, 
which become more homogeneous over the first three weeks of culture. There are no 
uniformly accepted definitive single or combination of cell surface markers for 
isolation of MPCs from uncultured samples [11].  In fresh bone marrow aspirate, cells 
of varying maturity in both hematopoietic and non-hematopoietic lineages are present, 
with varying levels of surface protein expression within each population, making 
separation of cells from distinct lineages difficult. During early culture, the proportion 
of hematopoietic cells committed to terminal differentiation is reduced via 
spontaneous apoptosis and removal due to non-adherence, leading to a more uniform 
population of mesenchymal cells.  In the present study, my hypothesis was that the 
immunophenotype of bone marrow cells was changed during the very early phases of 
MPC culture establishment as the cell population became more homogeneous.  The 
goal of this study was to evaluate both gene and protein expression of cell surface 
markers to characterize MPCs using flow cytometry and RT quantitative PCR (RT-
qPCR) throughout culture duration.  The results of this study may aid to improve MPC 
selection and isolation methods for research or therapeutic uses. 
 
Materials and Methods 
Study design: Candidate antibodies were tested for reactivity and specificity with 
equine cell surface antigens.  Subsequently, cell surface molecules of uncultured bone 
marrow cells were analyzed using flow cytometry.  Bone marrow cells were cultured 
and harvested on 2, 7, 14, 21, and 30 days for analysis of cell surface proteins and 
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gene expression.  All procedures were performed in compliance with institutional 
guidelines for research on animals. 
Antibody validation: To validate reactivity of antibodies with equine cells, peripheral 
blood cells were used as positive and negative controls.  Whole blood (30 mL) was 
collected from five horses for antibody validation.  Blood samples were drawn into 
preservative free heparin to a final concentration of 33 units/mL.  Candidate equine 
and human monoclonal antibodies tested are listed in Table 2.1.  Whole venous blood 
was processed prior to flow cytometry analysis using density gradient centrifugation to 
remove the majority of red blood cells as previously described [12]. 
Validation of antibody specificity: The CD44 and CD11a/CD18 antibodies have 
been previously validated as specific for their respective molecules in the horse ([13, 
14].  The CD11a/CD18 antibody (clone CZ3.2) identifies a non-covalently linked 
heterodimer consisting of a 180kDa α chain (CD11a) and a 95kDa β chain (CD18) 
using immunoprecipitation under reducing conditions[13, 14]. The CD44 antibody 
(clone CVS 18) identifies a heavily glycosylated molecule of 65-100kDa [13, 14].  On 
a 12% SDS-PAGE analysis, a “smear” was produced approximately in the 100kDa 
position, indicating that the precipitated molecule was heavily glycosylated.  The 
analysis was repeated after endoglycosidase F treatment of the precipitate, and a single 
76kDa band was produced in both reducing and non-reducing conditions [13, 14].  
The CD44 antibody has also been shown to react with protein produced by a cDNA 
encoding equine CD44 molecule in a COS cell expression system [15].   
For CD90, CD29, and CD45RB antibody validation analyses, whole cell 
lysates were prepared from fresh peripheral blood leukocytes and from red blood cells 
with platelets.  Western blot analyses were performed to determine if the reactive 
candidate antibodies bound proteins of the expected size based on previous literature, 
protein size similarity to other species, or predicted equine sequences.    The CD90 
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Table 2.1 Candidate antibodies tested to determine the changes in equine MPC cell 
surface antigens in uncultured samples and subsequent propagation of cells in culture.  
Alternate antigen names are listed in parentheses. 
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ANTIBODY 
TESTED 
SPECIES ANTIBODY IS PRODUCED 
AGAINST (COMPANY, CATALOG #) 
POSITIVE HUMAN CELLS POSITIVE EQUINE   
CONTROLS  
TESTED 
NEGATIVE EQUINE 
CONTROLS 
TESTED 
CD29 
(Integrin β1) 
Human (Beckman Coulter, 
Fullerton, CA; cat # 6603177)  
Lymphocytes, monocytes, 
granulocytes-low, platelets, 
fibroblasts, endothelial, NK cells, 
thymic /lymph node cells 
Lymphocytes, 
monocytes, 
granulocytes, 
platelets 
Red blood cells 
CD44 
(H-CAM) 
Equine (Serotec, Raleigh, NC; cat # 
MCA 1082) 
Hemato and non-hemato except 
platelets 
Leukocytes Red blood cells 
platelets 
CD90 
(Thy-1) 
Canine (VMRD, VMRD Inc, 
Pullman, WA;  cat # DH24A) 
Hematopoietic stem cell subset, 
neurons, fibroblasts, stromal cells
Granulocytes Lymphocytes 
CD45RB 
(LCA) 
Bovine (VMRD Inc, Pullman, WA; 
cat # DH16A) 
Granulocyte/ 
lymphocyte subpopulations 
Granulocytes, 
lymphocytes 
Red blood cells, 
platelets 
CD11a/CD18 
(Integrin αL,  
LFA-1) 
Equine (CZ 3.2 courtesy of Dr. D. 
Antczak, Cornell University; clone  
116.2D11B10) 
All leukocytes Leukocytes Red blood cells, 
platelets 
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Table 2.1 (Continued) 
Stro-1 Human (R &D Systems, 
Minneapolis  MN; cat # 
MAB1038) 
Human stromal cell 
precursors 
None available Leukocytes 
CD13 
(APN) 
Equine (Serotec, Raleigh, NC; 
cat # MCA 1084)  
Granulocytes, 
monocytes and their 
precursors, 
endothelium, epithelium  
Granulocytes, 
monocytes 
Lymphocytes 
SSEA 1 Mouse (DHSB University of 
Iowa; cat # MC-480)   
Human ES cells None available Leukocytes 
SSEA 3 Rat (DHSB University of Iowa; 
cat # MC-631)  
Human ES cells None available Leukocytes 
SSEA 4 Human (DHSB University of 
Iowa; cat # MC-813-70)  
Human ES cells None available Leukocytes 
CD34 
(Mucosialin) 
Human (BD Biosciences, San 
Jose, CA; cat # 555824 & cat # 
340666) 
Human hematopoietic 
stem and endothelial 
cells 
None available Mature leukocytes 
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Table 2.1 (Continued) 
CD, cluster of differentiation 
H-CAM, homing-associated cell adhesion molecule 
Thy-1, Thymocyte-differentiation antigen-1 
LCA, leukocyte common antigen 
LFA-1, lymphocyte function-associated antigen-1 
APN, Aminopeptidase N 
SSEA, stage-specific embryonic antigen 
T3, T cell antigen receptor complex 
CD3  
(T3) 
Equine (courtesy of Myra 
Blanchard, UC Davis; clone UC 
F6G-3.3) 
Mature T lymphocytes T lymphocytes Granulocytes, 
monocytes 
MHC class I Equine (CZ3 courtesy of Dr. D. 
Antczak, Cornell University; 
clone 117.1B12C11) 
Leukocytes and almost 
all nucleated cells in the 
body 
Leukocytes Early allantochorion 
cells 
MHC class II Equine (CZ11 courtesy of Dr. D. 
Antczak, Cornell University; 
clone 130.8E8D9) 
Mature lymphocytes Lymphocytes Granulocytes 
Mouse α Parvo Virus Canine (courtesy of Dr. D. 
Antczak, Cornell University;  
tissue culture supernatant) 
Parvo virus None available All equine cells should 
label negatively 
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antibody was expected to detect an approximately 17kDa protein, similar in size to the 
equivalent human protein.  Similarly, the CD29 antibody was expected to detect an 
approximately 130kDa protein based on the size of the human protein.  The CD45RB 
antibody was expected to have one or more bands less than 150kDa based on the 
multiple isotypes of the human protein.  To test the CD45RB and CD29 antibodies, 
proteins from cell lysates were resolved on 7.5% sodium dodecyl sulfate 
polyacrylamide (SDS-PAGE) gels, which were subsequently transferred to 
polyvinylidene fluoride (PVDF) membranes and probed with the relevant antibody.  A 
15% SDS-PAGE gel was used to resolve cell lysates for subsequent analysis of the 
CD90 antibody following protein transfer to a PVDF membrane.  
An immunoprecipitation was performed in addition to Western blot analysis 
for the CD29 antibody, using an unconjugated version of the antihuman CD29 
(Beckman Coulter, clone 4B4LDC9LDH8) used in this study.  A 7.5% SDS-PAGE 
gel was used to resolve the immunoprecipitated products.  Following protein transfer, 
the PVDF membrane was probed with antibody known to recognize human β1 
integrin (Calbiochem, clone 4B7-CP26).   
Bone marrow aspirate collection and cell isolation: Bone marrow aspirate was used 
to assess changes in cell surface markers over time and for tri-lineage (cartilage, bone, 
and adipose) differentiation.  Bone marrow aspirate was collected from the sternabrae 
of thirty five horses (11 males and 24 females, age range 6 months - 20 years) under 
standing sedation with xylazine hydrochloride (0.55 mg/kg IV) and local anesthesia 
using 2% lidocaine hydrochloride (10 mL/site).  Samples were collected in 
preservative free heparin (American Pharmaceutical Partners Inc, Schaumburg, IL) to 
a final concentration of 33 units/mL.    
The aspirate (60 mL) from each horse was diluted to 180 mL total volume 
using phosphate buffered saline + 0.5% bovine serum albumin.  The white blood cell 
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fraction of the sample was enriched and the majority of red blood cells were removed 
by layering each 30 mL aliquot of dilute sample on Ficoll-Paque Plus (Amersham 
Biosciences, Piscataway, NJ) for density gradient centrifugation, as described for 
antibody validation.  Samples were resuspended in 50 mL MPC culture media (see 
below) prior to cell counting using a hemocytometer.  Approximately 2-9 x 108 bone 
marrow mononuclear cells (BMMNC) were obtained per sample using this method.  A 
portion (~10 x 106 cells) of the uncultured bone marrow aspirate samples from all 
thirty five horses were analyzed using flow cytometry.  In a subpopulation of horses 
(n=8), samples of bone marrow aspirate before and following density gradient 
centrifugation were submitted for cytological analysis.   
Samples from some horses (n=14) were used only for antibody validation and 
were not cultured.  The remaining samples (n=21) were subsequently cultured as 
described below.  A fraction of the cultured bone marrow samples (n=6) were cultured 
for 14 days and then utilized for analysis of DNA content to determine the cell cycle 
state.  Samples from additional horses (n=3) were cultured for twenty-one days and 
then subjected to tri-lineage differentiation assays.  Some cultured samples (n=6) did 
not have sufficient cell numbers to complete analysis at all time points; yet they were 
used for flow cytometry at one or more culture time points to check for repeatability or 
alterations in cell surface protein expression.  Sufficient cell numbers for protein and 
gene expression analysis at all time points of culture were available from the 
remaining horses (n=6). 
MPC expansion in culture: BMMNCs were plated onto 10 cm diameter tissue 
culture plates at a density of approximately 300,000 cells/cm2 (20 x 106 cells/plate).  
Cells were cultured at 37°C in a 5% CO2, 95% air atmosphere at 5% humidity.  Cells 
were cultured in media containing Dulbecco’s Modified Eagle’s Medium (DMEM, 
glucose at 1000 mg/L), 2mM L-glutamine, penicillin (100 units/mL), streptomycin 
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(100 units/mL), basic fibroblastic growth factor (bFGF, 1 ng/mL) and 10% fetal 
bovine serum.  One-half of the media (5 mL) was removed at 24 hours of culture and 
replaced with fresh media.  Subsequently, media were exchanged every 72-96 hours.  
At sub-confluence of 70-90%, cells were passaged 1:3 using Accumax® cell 
dissociation solution (Innovative Cell Technologies Inc, San Diego, CA) and plated at 
a density of about 10,000 cells/cm2.  Approximately 10 x 106 cells from each sample 
was analyzed by flow cytometry for cell surface protein expression at two hours and 
on days 2, 5, 7, 14, 21 and 30 of culture.  Cells were analyzed at these time points to 
evaluate the changes in cell surface proteins over time, and to characterize the cells 
prior to performing differentiation assays. 
Flow cytometry analysis: Cell surface markers of putative stemness were assessed 
using flow cytometry.  Cells were pelleted in aliquots containing 1 x 106 cells and 
labeled for cell surface molecules selected from a panel of monoclonal antibodies 
known to define human MPCs (Table 2.1).  Cells were treated with a twenty minute 
blocking step using 10% normal goat serum in Fluorescent Activated Cell Sorting 
Buffer (FACS-Buffer; phosphate buffered saline containing 2.5% fetal bovine serum).  
The cells were pelleted, washed with FACS-Buffer and pelleted again.  Cell pellets 
were resuspended in fluorescent-conjugated or unconjugated primary monoclonal 
antibody and incubated for 45 minutes at 4°C.  Cells were then washed, a second 
fluorescent-conjugated goat anti-mouse Immunoglobulin G (IgG) or Immunoglobulin 
M (IgM) antibody (Fluorescein isothiocyanate (FITC) or Phycoerythrin (PE)- 
conjugated AffiniPure Goat Anti-Mouse IgG (H+L) or IgM µ Chain Specific, Jackson 
ImmunoResearch Laboratories, Inc. West Grove, PA) was applied to the unconjugated 
antibodies, and the samples were incubated for an additional 45 minutes at 4°C.  The 
CD29 antibody was directly conjugated with PE (read at FL2); all others were labeled 
with FITC-conjugated secondary antibody (read at FL1).  Cells were resuspended in 
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FACS-Buffer and analyzed on a FACSCaliber (Becton Dickinson Immunocytometry 
Systems, San Jose, CA) flow cytometer equipped with a 488µm argon laser and BD 
Cell Quest™ analysis software (BD Biosciences, San Jose, CA).  Cells not treated 
with antibody, and cells exposed to mouse anti-parvo-virus antibody and FITC or PE-
conjugated secondary antibodies were used as negative controls.  The settings for the 
flow cytometric analyses determined less than 2% positive cells for the control 
antibodies.  Data were collected on 1x105 cells for each sample regardless of size and 
granularity to prevent bias in gating.   
For culture expanded cells, flow cytometry analysis was performed on days 2, 
7, 14, 21, and 30 following isolation. Supernatant was removed and adherent cells 
were lifted from the plate using Accumax® solution (1 mL/15cm2) to prevent damage 
to cell surface proteins and avoid cellular clumping.  Cells were processed and 
analyzed by flow cytometry as described above, except dot plot settings were adjusted 
to a logarithmic scale in the cultured cells to include large, granular cells.  Flow 
cytometric analysis of cell surface molecule expression was performed in the gate 
determined to contain dividing cells based on the results from the propidium iodide 
DNA staining assay described below. Data for mean fluorescence intensity for the 
pertinent (reactive) antibodies was collected and compared between time points.  The 
mean fluorescence intensities of all cells (not just positive) in the relevant gate were 
recorded. 
Propidium iodide DNA staining assay for cell cycle analysis: Propidium iodide can 
be used to determine DNA content in cells and identify populations of cells 
undergoing division.  A reported feature of MPCs is their ability to proliferate [2].  To 
determine the region of cell division, samples (0.5 x 106 cells) from six cultures were 
collected on day 14 and resuspended in 500 µL hypotonic propidium iodide solution 
containing 0.05 mg/mL propidium iodide, 1 mg/L sodium citrate and 0.1% triton x-
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100 [16].  Samples were protected from light and incubated at 4°C until analysis.  
Samples were analyzed by flow cytometry on FL2.  Histograms were plotted for each 
cell population on a linear scale.  The DNA content is proportional to the mean 
fluorescence intensity, and consequently indicates the stage of cell division (G0/G1, S, 
G2, M; cells in sub G0 are dead) [17]. 
RNA extraction and One-Step Reverse Transcription and Quantitative 
Polymerase Chain Reaction (RT-qPCR):  Gene expression analysis was included to 
confirm negative protein results and account for kinetic changes in transcription and 
translation.  At the same time points when cells were analyzed by flow cytometry, 
RNA was extracted from approximately 1-3 x 106 cells of the corresponding samples 
using Trizol® (Life Technologies, Invitrogen, Carlsbad, CA) according to the 
manufacturer’s directions.  RT-qPCR was performed to provide supporting evidence 
that gene expression levels were consistent with cell surface protein expression levels.  
RNA quantity and quality were determined using a Nanodrop® spectrophotometer 
(NanoDrop Technologies, Inc, Wilmington, DE), and visualization of 18 and 28S 
ribosomal subunit bands on 0.8% agarose gels.  Gene segments were cloned and novel 
sequence data files were submitted to Genbank (accession numbers, EF442070 for 
CD13; EF442071 for CD29; EF576851 for CD45; EU881920 for CD90; and 
EU881921 for CD11a).  A portion of the CD44 gene was also cloned and agreed with 
previously reported data (X66862).   
Total RNA was reverse transcribed and amplified using the One-Step RT-PCR 
technique and the ABI PRISM 7900 HT Sequence Detection System (Applied 
Biosystems, Foster City, CA).  The primers and dual-labeled fluorescent probe [6-
FAM as the 5’ label (reporter dye) and TAMRA as the 3’ label (quenching dye)] were 
designed using Primer Express Software Version 2.0b8a (Applied Biosystems, Foster 
City, CA).  All probes and primers were designed using equine specific sequences 
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published in Genbank, or sequenced in our laboratory (Table 2.2).  Since several 
isoforms (five in humans) of CD45 exist, primers and probes were designed to detect 
as many equine isoforms as possible (equivalent to four of the five human isotypes).   
Two genes (CD45 and CD11a) did not reach a CT value in later time point samples.  
Therefore, normalized copy numbers/ng of RNA values for each gene were calculated.  
A quantity value of 1 was assigned to samples which did not reach a CT. 
MPC differentiation assays:  To verify that cultured bone marrow cells were capable 
of tri-lineage differentiation, 10 x 106 culture-expanded cells from three horses were 
used for adipogenic, osteogenic, and chondrogenic induction assays. 
Adipogenic induction: Aliquots of MPCs (0.2 x 104 cells /well) were treated 
with 5% rabbit serum (lot 24129, Innovative Research, Novi, MI) in culture media to 
induce adipogenesis [18].   
Media were changed at day 4 following induction.  Samples were collected on 
days 1, 3, and 7 post induction. To assess adipogenic differentiation, cells were fixed 
in 4% paraformaldehyde, incubated in a solution containing oil-red-O for 10 minutes 
to stain for lipid inclusions, and counterstained with hematoxylin.  Stained samples 
were imaged using standard microscopy and graded positive or negative for oil-red-O 
staining.  
Osteogenic induction: Aliquots of MPC (0.2 x 104 cells /well) were treated 
with 100nM dexamethasone, 10mM β-glycerophosphate and 50µM ascorbic acid (all 
Sigma-Aldrich, Inc. St. Louis, MO) in low glucose DMEM / 10% fetal bovine serum 
media.  Media were changed at day 4 for the 7 day culture samples.  Samples were 
collected on days 1, 3 and 7 following induction to assess early osteogenic 
differentiation.  To assess calcium accumulation, cells were fixed in 4% 
paraformaldehyde and incubated in 2% aqueous alizarin red S (Sigma) for 3 minutes, 
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Table 2.2 Primers and probes utilized in RT q-PCR of MPC marker genes.  The 18S ribosomal subunit was used to normalize gene 
expression. 
 
Gene Forward Primer Reverse Primer Probe 
18S 
5’CGGCTTTGGTGAC 
TCTAGATAACC-3’ 
5’-CCATGGTAGGC 
ACAGCGACTA-3’  
5’-TCGAACGTCTGCCCTA 
TCAACTTTCGAT-3’ 
CD44 
5’-TCCACCCCAA 
CTCCATCTGT-3’ 
5’-TGAAGCAATAGGT 
GTCGTACTGAGA-3’ 
5’-CCGCCAACAA 
CACGGGCG-3’ 
CD29 
5’-GACAAGGTGAGCAA 
TAGAAGGATAATC-3’ 
5’-TTGGTGGCATTG 
TTTTACCAAA-3’ 
5’-CACATCATTTTCCAAG 
TGACACTGTCCATCA-3’ 
CD90 
5’-CCGTGAGACAAA 
GAAGCATGTG-3’ 
5’-CCTGATGTTGTAC 
TTGCTGGTGAAG-3’ 
5’-TGAGCACACATAC 
CGCTCCCGGAC-3’ 
CD11a 
5’-GCCGAGATCCC 
AGTACATGAA-3’ 
5’-ACTGTGATGTTGA 
CTCCTTCCTTCT-3’ 
5’-AGTGCTCCCCTTCA 
GCCAGCAACAA-3’ 
CD45 
5’-TGATGATTTCTGG 
AGGATGATCTG-3’ 
5’-CACTTGTTCCTATT 
TCCTTCTTCACA-3’ 
5’-AAGCCACAGTCATTG 
TCATGGTCACTCG-3’ 
40
 41 
 
followed by counterstaining with hematoxylin.  Stained samples were imaged using 
standard microscopy and assessed for alizarin red staining.  Intracellular calcium 
concentration was measured using a commercially available kit (QuantiChrom™ 
Calcium Assay Kit, BioAssay Systems, Hayward, CA) in cell extracts collected on 
days 2, 3, 4, and 7 following induction.  Protein content in the same cell extracts was 
determined using the Bradford protein assay kit (Bio-Rad Protein Assay, Bio-Rad 
Laboratories, Hercules, CA) using bovine serum albumin as the standard.  Calcium 
concentration was expressed as µg Ca2+ /µg of total protein. 
Chondrogenic induction: Pellet cultures were generated using 5 x 105 cells 
/pellet with processing as previously described [19].  Pellet cultures were maintained 
in medium consisting of high glucose DMEM containing 100µg/mL sodium pyruvate, 
10 ng/mL TGF-β3, 100nM dexamethasone, 1x Insulin/Transferrin/Selenium (ITS+1) 
premix, 40 µg/mL proline and 25 µg/mL ascorbate-2-phosphate (all Sigma-Aldrich, 
Inc. St. Louis, MO).  Medium was replaced twice weekly.  Samples were collected on 
days 1, 3, 7, 14, 21 and 28 of culture.  Pellets were fixed with 4% paraformaldehyde, 
embedded in paraffin, and sliced into 4 micron sections.  Matrix metachromasia was 
assessed with Safranin-O/fast green staining. 
Statistical analysis: Gene expression data were categorized into four groups by 
culture duration: 1=less than one week; 2=one week; 3=two weeks; 4=three weeks or 
more.  Mean fluorescence intensity data were categorized into 5 groups by culture 
duration: 1=2 days; 2=one week; 3=two weeks; 4= three weeks; 5=four weeks.  
Calcium/protein ratio data were categorized into one of four groups by induction 
duration: 1=control (no osteogenic induction); 2=48 hours of induction; 3=72 hours of 
induction; 4=one week of induction.  Groups were compared using a One-Way 
ANOVA with a Tukey All-Pairwise Comparisons post hoc test.  A p-value of <0.05 
was considered significant. 
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Results 
Cytology of bone marrow aspirate: Cellular counts and distribution were compared 
between whole bone marrow aspirate and following gradient density centrifugation.  
Density gradient cell isolation was highly effective in removing RBC from the bone 
marrow aspirate with only 0.07% of original RBC remaining after isolation (Table 
2.3).   
Approximately 70% of nucleated cells were also lost during processing.  The 
monocytic lineage had the highest post-processing recovery at 47%, while the 
eosinophil lineage had the lowest recovery with only 5% of pre-processing numbers. 
Validation of antibodies against equine peripheral blood and bone marrow cells. 
Equine CD44, human CD29, canine CD90, and equine CD11a/CD18 antibodies were 
confirmed reactive to equine molecules using flow cytometry analysis (Figure 2.1 and 
Figure 2.2).  The bovine CD45RB antibody had questionable reactivity with equine 
molecules.  CD45RB data is included to demonstrate the importance of antibody 
validation, and the value of gene expression data in providing supporting evidence 
when protein expression detection is questionable.    
To confirm reactivity of the antibodies to equine molecules, isolated peripheral 
blood neutrophils (Figure 2.1, B) lymphocytes (Figure 2.1, C) and monocytes 
(Figure 2.1, D) were tested.  Results could then be used for comparison with fresh 
bone marrow cells of the same size and granularity (Figure 2.2).  In addition, for cells 
of the monocytic lineage, bone marrow was cultured for two hours and the adherent 
cells were collected and compared to uncultured bone marrow cells of the same size 
and granularity (see Figure 2.3, 2 hour sample).  There was increased mean 
fluorescence intensity for the CD44 and CD11a/CD18 molecules in both lymphocyte 
and monocyte lineage cells compared to uncultured bone marrow cells of the same 
size and granularity, confirming these antibodies were reactive to mononuclear cells.  
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Table 2.3 Bone marrow aspirate cell count and differential before and after density 
centrifugation cell isolation.  Cell count is calculated to reflect a 60mL BMA sample.  
Mean (Min/Max) n=8. 
 
 
 
 
Cell Type Pre-isolation 
(x 106) cells 
Post-isolation 
(x 106) cells 
% original post 
isolation 
Red blood cells 375,000 (299,000 / 
427,000) 
264 (45 / 565) 0.07 
Red cell precursors 754 (77 / 1,660) 181 (24 / 438) 24.00 
White cells and 
precursors 
847 (463 / 1,340) 310 (106 / 747) 36.60 
Neutrophils 590 (211 / 989) 216 (44 / 558) 36.61 
Monocytes 42 (19/ 74) 20 (6 / 41) 47.28 
Mitotic myeloid 
(lineage was not 
classified) 
23 (2/ 63) 7 (2/ 15) 28.95 
Lymphocytes (and 
precursors) 
191 (106 / 266) 61 (27/ 112) 31.99 
Eosinophils 15 (6/ 33) 1 (0 / 2) 5.16 
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Figure 2.1 Flow cytometric analyses of cell surface molecule expression in isolated 
peripheral blood cells. Dot plot distribution of uncultured peripheral blood cells 
isolated using A1) gradient density centrifugation or A2) carbonyl iron incubation 
followed by gradient density centrifugation.  B-D) Histogram analysis of mean 
fluorescence intensity of cell surface molecule expression in the gated areas (Regions 
1, 2, and 3, respectively, for isolated peripheral blood cells).  The R1 gate corresponds 
to the size and granularity of neutrophils; R2 lymphocytes; and R3 monocytes.  The 
shaded curves represent negative isotype control staining.  Open lines represent the 
labeling for the cell surface markers indicated.  The expected labeling pattern for each 
marker is indicated in parenthesis.  Note that CD44, CD29, and CD11a/CD18 are 
detected in all three regions, while CD90 is detected in R1 (neutrophils) and CD45RB 
is detected in only a small population of R2 (lymphocytes) and R3 (monocytes).   
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Figure 2.1 (Continued) 
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Figure 2.1 (Continued) 
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Figure 2.2 Flow cytometric analyses of surface molecule expression in uncultured 
bone marrow cells. A) Dot plot distribution of uncultured bone marrow cells isolated 
using gradient density centrifugation  B-E) Histogram analysis of mean fluorescence 
intensity of cell surface molecule expression in the gated areas (regions 1, 2, 3 and 4, 
respectively).  Cells in region 1 are equivalent in size and granularity to neutrophils; 
region 2, lymphocytes; region 3, monocytes; and region 4, red blood cells and 
platelets.  The shaded curves represent negative isotype control staining; open lines 
represent the labeling for the cell surface markers indicated in the left-hand side.  Note 
the variation in the CD44 and CD11a/CD18 expression in Region 2 gated cells 
between uncultured bone marrow (C) and peripheral blood isolated cells (see Figure 
2.1, C).  Also, the expression of these molecules in Region 3 is different between 
uncultured (D) and isolated peripheral blood cells (see Figure 2.1, D) or 2-hour  
cultured bone marrow cells (Figure 2.3).  (WBC, white blood cell, RBC, red blood 
cell) 
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Figure 2.2 (Continued) 
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Figure 2.3 Flow cytometric analyses of cell surface molecule expression in bone 
marrow cells over increasing culture periods.  Part A. Dot plot distribution of bone 
marrow cells isolated using gradient density centrifugation followed by culture of 
indicated duration. Part B.  Histogram analysis of mean fluorescence intensity of cell 
surface molecule expression in the gated area (Region 3).  The shaded curves 
represent negative isotype control staining; open lines represent the labeling for the 
cell surface markers indicated in the left-hand side.  At two hours, adherent cells gated 
in Region 3 displayed a molecular profile consistent with monocyte lineage, while 
later time points revealed changes, particularly in CD90 and CD11a/CD18 expression.  
At 48 hours, the presence of multiple cell types was evidenced by several peaks in 
antibody labeling for CD44, CD29 and CD90.  By 14 days, when cells display a 
fibroblastic morphology in culture, putative MPCs were positive for CD44, CD29 and 
CD90, while negative for CD45 and CD11a/CD18. This staining pattern is retained 
throughout long term culture. 
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Figure 2.3 (Continued) 
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By analogy to peripheral blood cells, region 1 included cells of the neutrophil lineage, 
region 2 to the lymphocyte lineage, and region 3 to the monocytic lineage.  
Interestingly, CD44, and CD11a/CD18 antibodies were variably immunoreactive in 
freshly isolated bone marrow cells.  Cells in region 1 were CD44hi, CD29hi, CD90hi,  
CD11a/CD18hi and CD45RBhi (see Figure 2.2, B).  Regions 2 and 3 contained bone 
marrow cells that were CD44lo, CD29hi, CD90lo, CD11a/CD18lo and CD45RBlo 
(Figure 2.2, C and D), suggesting these regions contained cell types other than 
mature mononuclear cells.  The monoclonal antibodies against equine MHC class I, 
equine MHC class II and equine CD3 labeled the expected cell populations, and were 
used as internal controls for subsequent flow cytometry assays 
 Other antibodies tested were found to be non-reactive to equine molecules or 
differed in expression from MPCs of other species.  The specific lot of monoclonal 
antibody against equine CD13 and several human antibodies tested, including Stro-1, 
SSEA 1, SSEA 3, SSEA 4, and CD34 did not label equine cells using flow cytometry.  
No equine-specific positive controls, such as embryonic stem cells, were available to 
confirm the negative findings.   
Validation of protein specificity: Western blot analysis alone was not clear to 
determine specificity of the CD29 antibody reaction with equine blood cells.  No 
distinct band was detected on multiple attempts to analyze CD29 antibody binding.  It 
was proposed that this antibody did not recognize the denatured protein.  The 
Beckman Coulter CD29 antibody, clone 4B4LDC9LDH8, has been extensively used 
for immunoprecipitation in human cells [20].  Immunoprecipitation using clone 
4B4LDC9LDH8 antibody followed by Western blot analysis with the Calbiochem 
clone 4B7-CP26 antibody confirmed the CD29 antibody (4B4LDC9LDH8) reacted 
with a single protein of approximately 130kDa (Figure 2.4).  Western blot analysis 
was successful in demonstrating the CD90 antibody reacted with a protein of 
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Figure 2.4 Western blot analyses to test the specificity of CD29 and CD90 antibodies 
in equine peripheral blood cells.  A1. Three-dimensional image of a western blot 
following immunoprecipitation using anti ()-human CD29 antibody (Beckman 
Coulter, clone 4B4LDC9LDH8) with equine blood cells and probing with -human 
β1 integrin antibody (Calbiochem, clone 4B7-CP26). White blood cell (WBC) or red 
blood cell/platelet (RBC) lysates incubated with -CD29 antibody retained a protein 
band, of approximately 130kDa (*). Arrow indicates the heavy chain of IgG.  A2. 
Molecular size standards.  B1. Three-dimensional image of a western blot of equine 
WBC or RBC lysate probed with an -canine CD90 antibody (VMRD, clone 
DH24A). An approximately 17kDa protein band was detected in equine WBC lysate 
(*). B2. Molecular size standards.   
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appropriate size of 17kDa (Figure 2.4) in equine peripheral blood leukocytes, and was 
not detected in red blood cells or platelets.  The CD45RB antibody did not react with a 
protein of expected size of ~150kDa on Western blot analysis. Instead, multiple poorly 
defined protein bands were noted of varying sizes (data not shown).  
DNA content analysis to determine cell cycle stage of cultured bone marrow cells:  
DNA content analysis was useful for identification of the region of interest (Gate 3) on 
the dot plot of cultured MPC, and subsequent flow cytometry analysis was restricted 
to this cell population (Figure 2.5).  Proliferating cultured bone marrow cells were 
identified in Gate 3 by the high number of cells in the S/G2/M phase based on their 
increased DNA content [17].  Cells in S/G2/M were consistently located only in this 
gate.  In contrast, in Gate 1 (R1) and Gate 2 (R2), the majority of cells are presumed to 
be dying (subG0).   
Cell surface marker expression in cultured bone marrow cells changes over time in 
culture: After two hours of culture, adherent mononuclear cells displayed an antibody 
labeling pattern of CD44hi, CD29hi, CD90lo and CD11a/CD18hi, CD45RBlo (Figure 2.3).  
By two days of culture, expression of CD11a/CD18 began to decrease, while CD90 
expression was increased compared to expression levels at two hours.  In Gate 3, there 
appeared to be a heterogeneous cell population as evidenced by multiple peaks in CD44, 
CD29, and CD90 mean fluorescence intensity. Over the next several days there was a 
population shift as cells with high CD90 expression decreased in population percentage 
compared to cells with lower mean fluorescence intensity for CD90 expression.  On day 
seven, CD11a/CD18 cell surface expression further decreased, while CD90 expression 
began to increase following a trough in CD90 expression from days two through seven.  
By fourteen days, adherent cells in culture were CD44hi, CD29hi, and CD90hi, 
CD11a/CD18neg and CD45RBneg; these cells displayed a fibroblastic morphology 
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Figure 2.5 Cell cycle analysis of bone marrow cells in culture. (A) Flow cytometry 
dot plot (side scatter, SSC x forward scatter, FSC) demonstrates the distribution of 
three cell populations (R1, R2, R3) in bone marrow aspirate cultured for 14 days.  (B)  
Flow cytometry histogram analyses of each gated area in Figure 2A reveals the cell 
cycle status according to their DNA content (stained with propidium iodide).  In Gates 
1 (R1) and Gate 2 (R2), the majority of cells are within sub-G0 and G0/G1, consistent 
with cell death.  In Gate 3 (R3), cells are undergoing division, and 1/3 of cells are in 
S/G2/M phase.  Therefore, the flow cytometric cell surface molecular analysis 
reported in Figure 3 was performed with cells gated in Region 3 (R3). 
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characteristic of MPC (data not shown).  This pattern of molecule expression was 
retained at 21 and 30 days for all MPC samples.  At all time points (2 hours, 2, 7, 14, 
21, and 30 days), adherent bone marrow cells in culture showed a consistent labeling 
pattern with the results described above in all samples analyzed. 
The mean fluorescence intensity varied by culture duration for several of the 
antibodies analyzed (Figure 2.6).  The mouse anti-parvo virus negative control 
antibody (P=0.19) did not vary significantly over time.  The mean fluorescence 
intensity of CD44 expression was also not significantly different over time (P=0.57). 
The mean fluorescence intensity of CD29 expression was significantly greater in cells 
cultured fourteen days or more compared to earlier time points (P≤0.001).  Mean 
fluorescent intensity for CD90 expression was significantly different (P=0.01) over 
time, with a decrease at seven days compared to other time points.  The mean 
fluorescence intensity of CD45RB was not significantly different between time points 
(P=0.11), with all samples having minimal protein detection, comparable to the 
control negative antibody.  Finally, CD11a/CD18 expression decreased significantly 
over time (P≤0.001) in early samples compared to samples cultured fourteen days or 
more.  Targeted analysis using flow cytometry revealed a number of significant 
differences in protein marker expression between bone marrow cells cultured for 
different time periods. 
Gene expression in cultured bone marrow cells: Gene expression data followed a 
consistent pattern with cell surface protein expression at all culture time points.  In 
samples where gene expression was high, the corresponding antibody mean 
fluorescence intensity was also detected at high levels.  The same pattern was true for 
samples with low or undetectable levels of gene expression.  There was little or no 
increase in mean fluorescence intensity for the corresponding molecule in these 
samples compared to the mean fluorescence intensity of the control negative antibody.   
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Figure 2.6 Flow cytometry analysis of mean fluorescence intensity over time in 
cultured bone marrow cells. The mean fluorescence intensity of selected markers 
was tested by one-way ANOVA and Tukey’s All-Pairwise Comparisons (n=6 ± SE).  
There were significant (P≤0.05) differences between mean fluorescence intensity over 
time for several antibodies [CD29 (B), CD90 (C), and CD11a/CD18 (F)], but no 
significant differences for the CD44 (A), CD45RB (E), or the control negative MxP  
(D) antibodies.  CD45RB data was included to demonstrate that mean fluorescence 
intensity using this antibody was similar to the control negative antibody.  
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Since the grouping of samples for statistical analysis varied between gene and protein 
expression, and the flow cytometry analysis could be targeted to the cell population of 
interest, slight differences were detected in gene expression data from the statistical 
results of mean fluorescence intensity reported above.      
CD44 gene expression was present in all samples but changed over time (Figure 2.7).  
Early samples (≤ 7 days) had significantly more CD44 expression compared to 
samples cultured for 14 days or more (P< 0.001).   CD29 gene expression was also 
high and present in all samples, but no significant differences were detected based on 
culture duration (P=0.19).  Expression of CD90 varied with culture duration and was 
significantly greater in cells cultured for 21 days or more compared to all earlier 
samples (P< 0.001).  Gene expression of CD11a and CD45 was present in all samples 
cultured 7 days or less.  In contrast, samples cultured 14 days or longer failed to reach 
a CT value with a threshold of 40 cycles in 60% of samples analyzed for CD11a, and 
84% for CD45.  For CD11a, early duration culture samples had significantly more 
expression than samples cultured 14 days or more (P< 0.001).  CD45 gene expression 
levels also significantly decreased with increasing culture duration (P<0.001). 
Differentiation assays: Tri-lineage differentiation capacity of cultured bone marrow 
cells was confirmed through in vitro adipogenic, osteogenic and chondrogenic assays.  
Following induction, histochemical staining for adipogenesis and osteogenesis in short 
term (≤7days) assays and longer duration chondrogenic induction (up to 4 weeks) 
were consistent with previous reports of MPC differentiation potential [2].  In the 
description by Pittenger et al., lipid vacuoles were detected within 48 hours of 
induction under adipogenic conditions, calcium accumulation continued for at least 
three weeks, and Safranin O staining increased over the four week time period under 
chondrogenic conditions.   
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Figure 2.7 Gene expression kinetics in cultured bone marrow cells. The gene 
expression of selected markers over increasing culture durations was tested by one-
way ANOVA and Tukey’s All-Pairwise Comparisons (n=6 ± SE).  There were 
significant (P ≤ 0.05) differences between gene expression (copy number) over time 
for most genes [CD44 (A), CD90 (C), CD11a (D) and CD45 (E)], but no significant 
difference for CD29 (B) gene.  For CD11a and CD45, the majority of samples 
cultured 14 days or longer did not reach a CT value. Samples with gene expression 
below the detectable limit (*) were assigned a quantity of 1 to permit statistical 
analysis.  Schematic relative gene expression changes during the establishment of 
MPC cultures are shown in F.   
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Figure 2.7 (Continued) 
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Under adipogenic culture conditions, MPCs accumulated a large amount of 
lipid vacuoles in their cytoplasm, while control samples had no appreciable staining 
for lipid (Figure 2.8).  Osteogenic culture conditions induced a change in cell 
morphology from fibroblastic to a stellate or cuboidal shape within 7 days (Figure 
2.8). Early calcium accumulation was evidenced by alizarin staining in the first 7 days 
of culture.  Calcium accumulation in MPCs following osteogenic induction was 
significantly increased by day 7 compared to earlier time points and control samples as 
assessed using calcium/protein ratios of the samples (P=0.003).  Control cells had 
0.347± 0.038 µg Ca2+ /µg total protein which increased to 0.490 ± 0.120 µg Ca2+ /µg 
total protein within 24 hours of osteogenic induction.  By 72 hours, content was 0.756 
± 0.226 µg Ca2+ /µg total protein and by 7 days the ratio was 1.502 ± 0.467 µg Ca2+ 
/µg total protein, a 3-6 fold increase in relative calcium compared to control 
conditions.  During chondrogenic induction, an increase in pellet size was noted with 
increasing culture duration over the 28 day culture period.  The pellets also had 
progressively more matrix metachromasia as evidenced by enhanced staining with 
Safranin-O stain with increased culture duration (Figure 2.8).   
 
Discussion   
In this study temporal changes in cell surface protein and gene expression in 
MPC in culture were demonstrated. Based on the literature, it was anticipated that 
established equine MPC cultures would be negative for CD45RB and CD11a/CD18, 
and positive for CD44, CD29, and CD90 (Thy-1)[2][21].  Protein expression data in 
early cultured (2 hour) bone marrow mononuclear cells comprised CD44hi, CD29hi, 
and CD11a/CD18hi positive cells, with a smaller population of CD90lo and CD45RBlo 
positive cells.  Established cultures of MPC were robustly positive for CD44, CD29 
and CD90, becoming negative for CD11a/CD18 and CD45RB.  Gene expression data 
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Figure 2.8 Differentiation assays using cultured equine MPC.  A-D lipid induction 
with Oil-Lipid-O staining, E-H osteogenic induction with Alizarin staining, I-L 
chondrogenic induction with Safranin O/fast green staining.  A,E control MPC; B,F 24 
hour induction; C,G 72 hour induction; D, H 7 day induction.  I 3 day induction; J 1 
week induction; K 2 week induction; L 4 week induction. 
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followed the same pattern, in which established cultures retained expression of CD44, 
CD29 and CD90, whereas levels of CD11a and CD45 dropped below the level of 
detection by 14 days of culture. The molecules detected by these antibodies were 
found to have protein and gene expression patterns consistent with results of protein 
expression in cultured MPCs of other species [2, 4, 22].  Equine MPCs had positive 
expression of CD44, CD29, and CD90 and negative expression of CD11a/CD18 and 
CD45RB similar to flow cytometry analysis of expanded human bone marrow cells by 
Pittenger et al.  Sung et al. noted CD44 and CD29 were present in expanded mouse 
MPCs and CD45 was absent.  Although other studies have found similar antibody 
labeling in established cultures of 14 days or more [21], none have specifically 
documented changes in gene and protein expression over time from isolation through 
two weeks and beyond.   
In bone marrow samples cultured for 48 hours, a mixed population of cells was 
still present despite selecting for strongly adherent cells by vigorously washing the 
plates to prior to sample collection.  This was evidenced by multiple peaks in CD44, 
CD29 and CD90 mean fluorescence intensity and side scatter distribution (data not 
shown) of cells in flow cytometry.  At least two populations of cells expressing CD90 in 
different mean fluorescence intensities were detected at the protein level. This molecule 
is highly expressed in equine neutrophils.  Neutrophils are known to enter apoptosis 
spontaneously within 24 to 36 hours of culture [2], so they would be progressively 
removed during subsequent media changes, and the relative levels of CD90 gene and 
protein expression of remaining cells should decrease proportionally during early 
culture.  Over time, the cells expressing CD44, CD29 and CD90 became more 
homogeneous (see Figure 2.3, 48 hours versus 14 days) based on the flow cytometric 
histogram analyses.  Expression of CD44 or CD29 molecule alone is not useful to 
determine putative MPCs because they are not unique to MPCs.  Although these 
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molecules are not included in the minimal criteria for defining human multipotent 
mesenchymal stromal cells, they may play a role in equine characterization studies as 
part of a combination of positive and negative markers, since expression of the 
molecules is sustained in long term culture [23].   
Gene expression data was especially useful to confirm negative results when 
analyzing CD45RB cell surface protein expression, as CD45RB expression was 
weakly/inconsistently detected in isolated peripheral blood leukocytes and bone 
marrow cells when tested by flow cytometry.  The bovine CD45RB antibody used in 
this study had previously been validated for the horse [21].  Nevertheless, protein 
detection using flow cytometry can be affected by variability in the reagents 
(monoclonal antibody product lot or secondary conjugated-antibodies) or instrument 
settings used.  Therefore, validation of reagents and standardized data collection and 
analysis are important for consistency in results.  I have included the CD45RB data 
specifically to demonstrate the importance of reagent validation.  Gene expression 
data can be a useful, complementary tool for cellular immunophenotyping when 
protein expression data is inconsistent, or reagents are not readily available, as it was 
for CD45RB.  In the future, with adequate reagents to the equine species, the protein 
expression for CD45 can be confirmed. 
An interesting observation of this study was the difference in cell surface 
molecule expression between fresh bone marrow mononuclear cells and peripheral 
blood leukocytes, or short term (2 hour) cultured bone marrow mononuclear cells for 
CD44 and CD11a/CD18.  To my knowledge, other studies that have analyzed and/or 
antibody sorted fresh marrow did not account for this difference in protein expression 
[24, 25].  Mitchell et al. [26] reported initially low levels of CD44 protein expression 
in uncultured cells, which increased during successive passages.  The lack of antigen 
identification on freshly isolated cells from the bone marrow can be misleading since 
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cells may not be sufficiently mature to express proteins characteristic of their lineage 
especially when trying to classify hematopoietic versus non-hematopoietic cells.  
Therefore, I would suggest a short duration culture (e.g. two hours) to better classify 
adherent bone marrow cells based on their molecular expression of hematopoietic 
markers (e.g. CD11a/CD18).  
Lack of expression of Stro-1, SSEA1, SSEA3, SSEA4, and CD34 in isolated 
bone marrow and cultured cells could not be verified due to unavailability of equine 
specific reagents, and the lack of reactivity of human reagents to horse molecules.  
Lack of positive controls prevents the validation of these reagents for equine 
molecules.  The lack of cross-reactivity of several human antibodies to equine 
molecules is not surprising given the recent work by Ibrahim S. et al. [27] which 
reported only 14 out of 379 monoclonal human antibodies tested cross-reacted in a 
cell-type specific manner with equine leukocytes.  The findings of these studies 
emphasize the importance of rigorous testing with controls when using xenogenic 
antibodies. 
Density gradient centrifugation of equine bone marrow aspirate was successful 
in removing nearly all of the red blood cells and allowed for analysis of the mixed 
mononuclear cell fraction in fresh samples using flow cytometry.  Approximately 30% 
of nucleated cells were retained for analysis which is identical to that of human bone 
marrow aspirate using the same technique [28].  The number of mononuclear cells in 
equine aspirates following isolation were also proportionate to human bone marrow 
mononuclear cell counts on a per ml of aspirate basis, and 3-5X more total 
mononuclear cells were harvested/isolated from equine since 3-5X the volume of 
aspirates were collected.  Equine bone marrow samples provided sufficient cell 
numbers to allow analysis at multiple early time points.   
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An accepted characteristic of MPC is the highly proliferative nature of this cell 
type [2].  Previous studies have not attempted to target the dividing cell population when 
analyzing MPC markers.  Cell cycle analysis of cultured bone marrow cells was a 
simple way to identify the dividing population.  Characterization of surface protein 
expression for this specific population may be more accurate than ungated analysis, as 
cells from the non-dividing populations are removed from analysis.  In actively dividing 
cultures, I have noted approximately 40-65% of the total cells are located in the region 
of interest (Region 3).  As cultures senesce, I have noted a drop in the percentage of 
cells located in Region 3 to 10-30% (data not shown) with a shift in cellular distribution 
towards Regions 1 and 2 of the dot plot; and decreases in mean fluorescence intensity of 
CD90 and CD44 expression in Region 3.  Not only does analysis of cellular markers in 
Region 3 focus on the dividing cell population, relative cell distribution between the 
three regions also reflects the overall proliferative activity of the culture.  In this study, 
targeted analysis using flow cytometry to assess mean fluorescence intensity of cells 
only in the region of interest allowed for additional significant differences to be 
identified between culture time periods compared to analysis of gene expression alone.    
Much work remains to be done in the full characterization of the equine MPC.  
This study presents a preliminary molecular profile using both gene and protein 
expression levels of bone marrow nucleated cells from isolation to one month in 
culture.  Understanding the early changes in cultured bone marrow cells may promote 
identification of cellular markers unique to early MPC’s and help distinguish them 
from hematopoietic and other cell types.  My results suggest that freshly isolated cells 
from bone marrow aspirate do not express surface proteins uniformly due to varying 
stages of cellular maturity.  This may lead to less accurate cell sorting when using 
freshly isolated bone marrow cells.  For example, use of the cell surface markers 
CD44 or CD11a/CD18 to sort freshly isolated bone marrow cells may incorrectly 
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select immature hematopoietic cells expressing low levels of these proteins.  Short 
term culture allows selection of adherent, more mature cells, leading to more accurate 
classification of cell lineage and the potential for mesenchymal differentiation.  
Taking advantage of changes in marker expression during culture establishment may 
be beneficial for enhanced isolation of MPC from bone marrow aspirate or other tissue 
sources.   
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Abstract  
A long-term goal of my dissertation research is to identify both positive and 
negative MPC cell surface markers to facilitate isolation of equine MPCs in future cell 
sorting studies.  One of the reported features of mesenchymal progenitor cells (MPCs) 
in humans and other species is lack of expression of the cluster of differentiation (CD) 
marker CD14, also known as the lipopolysaccharide receptor (LPS-R).  There are no 
reports of either upregulation or downregulation of CD14 gene or protein expression 
in equine MPCs.  My aim was to evaluate CD14 expression patterns in equine bone 
marrow as a potential negative MPC marker.  My hypothesis was that cells negatively 
selected by CD14 expression (non-hematopoietic cells) would enrich MPC colony 
formation compared to the CD14 positive hematopoietic and unsorted fractions.  Bone 
marrow aspirate was obtained from twelve horses and processed by density gradient 
centrifugation.  Fresh and cultured cells were analyzed by a combination of flow 
cytometry and reverse transcriptase quantitative polymerase chain reaction (RT-
qPCR).  In fresh marrow aspirate, cells of early hematopoietic origin did not uniformly 
express CD14 protein or other hematopoietic specific markers such as CD11a/CD18, 
complicating the distinction of hematopoietic versus non-hematopoietic cells when 
assessed using flow cytometry.  It was proposed that many freshly isolated 
hematopoietic cells from the bone marrow were not yet expressing cell surface 
proteins normally associated with mature peripheral blood cells.  Short term (2 day) 
culture allowed enrichment of adherent bone marrow cells.  The enriched cell types 
included adherent myeloid hematopoietic cells, which now expressed cell surface 
proteins associated with peripheral blood cells, and putative MPCs.  The distinction 
between hematopoietic and non-hematopoietic cell lineages, using a differentially 
expressed protein, could easily be made following 2 days of culture.  A cell sorting 
experiment was performed to exploit the difference in CD14 protein expression 
 80 
between adherent hematopoietic (CD14 positive) and mesenchymal (CD14 negative) 
lineages to enrich for MPC colony formation.  Magnetic activated cell sorting 
(MACS) was used to separate bone marrow cells from six horses based on CD14 
expression after 2 days of culture.  Flow cytometry and RT-qPCR were used to 
evaluate sort efficiency and analyze cultured cells over time.  Quantitation of MPC 
colony formation in the sorted cell fractions were assessed at day 7 and compared to 
each other and the unsorted cell fraction.  Cells positively selected for CD14 
expression were significantly more likely to form MPC colonies than both unsorted 
and negatively selected cells (P ≤ 0.005).  Further, MPCs from all three (CD14 
positive, negative and unsorted) fractions maintained low levels of CD14 expression 
in long term culture and could upregulate CD14 gene and protein expression when 
stimulated with lipopolysaccharide (LPS).  An additional experiment demonstrated 
that the equine CD14 cell surface molecule was trypsin labile on MPCs, offering a 
plausible explanation for the discrepancy with negative CD14 protein results reported 
in other species.  Only certain lineages of hematopoietic cells (e.g. monocytes, 
macrophages, dendritic cells, activated B lymphocytes and to a lesser extent 
neutrophils) are known to express CD14.   By definition, MPCs of other species are 
thought to be non-hematopoietic in lineage because they lack expression of specific 
hematopoietic molecules such as CD14.  The expression of CD14 by equine MPCs 
raises the question whether these cells are truly derived from a non-hematopoietic 
lineage.  It is possible they are a differentiated descendant of a CD14 positive cell, or 
they may have simply been misclassified previously as negative for CD14 expression. 
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Introduction 
Mesenchymal progenitor cells (MPC) are found in bone marrow and other 
tissues, and are defined using a number of criteria [1].  MPC are adherent to tissue 
culture plastic and can differentiate to osteoblasts, adipocytes, and chondroblasts in 
vitro.  Besides these features, in humans, these cells are defined by cell surface 
molecule expression of the cluster of differentiation (CD) molecules CD105, CD73, 
and CD90 and the lack of expression of CD45, CD34, CD14 or CD11b, CD79alpha or 
CD19, and HLA-DR in culture expanded cells [1].  Classification of MPCs using the 
CD cell surface phenotype has been utilized as supporting evidence of a unique cell 
population that can be distinguished from hematopoietic and other cell lineages. 
The CD nomenclature system classifies monoclonal antibodies by the epitope 
they recognize on the cell surface [2, 3].  Human Leukocyte Differentiation Antigen 
(HLDA) workshops have summarized the antibody clusters grouped by the CD 
nomenclature system, and many more surface molecules continue to be defined, with 
only an estimated 10-20% of all surface molecules defined to date [4].  If two or more 
specific monoclonal antibodies bind to the molecule of interest, a CD designation is 
assigned.  If only one monoclonal has been shown to bind, a provisional indicator “w” 
is included in the name.  More than 350 designations have been classified for humans. 
Although the CD classification system was initially developed for leukocytes, a 
number of other cell types, including stromal cells, have been phenotyped based on the 
presence or absence of CD molecules [5].   
Characterization studies of established human MPC cultures using 
differentiation assays, gene expression analysis, and cell surface protein markers have 
been performed for nearly a decade [6].  Most studies evaluate MPC cell surface 
markers and gene expression after population expansion in culture in order to obtain 
sufficient cell numbers for analysis [7-10].  However, there are reports of conflicting 
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results in MPC marker protein expression patterns when comparing phenotypes of 
freshly sorted MPCs to expanded MPCs [11, 12].  These studies suggest that the 
phenotype of MPCs is dynamic during isolation and culture processes.      
One of the defining features of MPCs in humans and other species is lack of 
expression of the CD14 marker, also known as the lipopolysaccharide receptor (LPS-
R) on their cell surface.   The CD14 protein epitope is an important component of the 
innate immune system for detection of lipopolysaccharide (LPS).  The LPS-R 
associates in a complex (53-55kDa) with an adaptor protein known as MD-2 and the 
toll-like receptor 4 (TLR4) signaling proteins.  The CD14 receptor can only bind LPS 
when lipopolysaccharide-binding protein (LBP) is also present.  The LPS-R has a 
molecular weight of 40kDa when separated from the complex.    Only certain lineages 
of hematopoietic cells (e.g. monocytes, macrophages, dendritic cells, activated B 
lymphocytes, and to a lesser extent neutrophils), are known to express CD14.  
Therefore, CD14 would be a candidate cell surface marker to differentiate between 
adherent (primarily myeloid) CD14 positive hematopoietic cells and MPCs, which 
should be negative for CD14 expression. 
Despite many reports that suggest the CD14 cell surface molecule is absent in 
MPCs, a few reports have suggested otherwise.  In 2003, Kuwana et al. described 
selection of CD14 positive cells from human peripheral blood which could then be 
differentiated into numerous mesenchymal tissues including fat, bone, skeletal muscle 
and cartilage in vitro [13], with a later study demonstrating differentiation into 
cardiomyocytes [14].  This group referred to the CD14 positive population of interest 
as monocyte derived mesenchymal progenitors (MOMP).  Other groups have named 
peripheral blood cells with similar phenotype and differentiation capacity 
programmable cells of monocytic origin (PCOM) [15].  Pufe et al. demonstrated that 
these cells were able to form collagen type II producing chondrocytes in vitro.  Using 
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an antibody against Mac-1 (an epitope specific to monocyte/granulocyte lineage cells; 
also known as CD11b/CD18), Sera et al. demonstrated that adipocytes could be 
derived from hematopoietic cells of monocyte/macrophage lineage [16].  Incidentally, 
these studies all used ethylenediaminetetraacetic acid (EDTA) for cell harvest prior to 
analysis using flow cytometry, which will become important in later discussion with 
respect to trypsinization.  In another study, putative MPCs from cord blood have been 
isolated with the initial cell phenotype of CD45+,CD105+, CD14+, CD49a+, CD49f+, 
CD44+ and CD34-.  Later, the culture passaged cells were CD45-, CD14-, CD34- and 
weakly CD105+ [17].   
Most MPC characterization studies have utilized trypsin, a serine protease, for 
cell harvest prior to flow cytometric analysis.  Trypsin cleaves peptide chains at the 
carboxyl side of lysine or arginine.  It is commonly used to disrupt adherent cells to 
permit cell passage or harvest in tissue culture applications.  Trypsin has previously 
been shown to cleave a number of cell-membrane molecules, including CD14 [18].  It 
is possible that trypsin has interfered with detection of the CD14 epitope on candidate 
cells in previous MPC studies.  
In this study, my aim was to evaluate CD14 expression patterns in equine bone 
marrow as a potential negative MPC marker.  My hypothesis was that bone marrow 
cells negatively selected for CD14 expression would enrich for MPC colony 
formation.  Fresh and cultured cells were analyzed by a combination of flow 
cytometry and reverse transcriptase quantitative polymerase chain reaction (RT-
qPCR).  I proposed that a mouse anti-equine CD14 antibody could be used to separate 
the adherent CD14 positive hematopoietic cell fraction (primarily neutrophil and 
monocyte lineages) from the putative MPCs using magnetic activated cell sorting 
(MACS).  The MACS technique was used to separate bone marrow cells from six 
horses based on CD14 expression after two days of culture into one of three fractions 
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1) unsorted, 2) CD14 positive, and 3) CD14 negatively selected.  Flow cytometry and 
RT-qPCR were used to evaluate sort purity and analyze cultured cell fractions over 
time.  Quantitation of MPC colony formation was assessed at day seven by comparing 
the numbers of colonies in each fraction relative to initial cell numbers plated 
following MACS.  In addition, I tested the responsiveness of putative MPCs to LPS 
stimulation and evaluated the equine CD14 epitope to determine if it was trypsin labile 
as assessed using flow cytometry and RT-qPCR. 
 
Materials and Methods 
Study design: The mouse anti-equine CD14 antibody (clone 105; B. Wagner, Cornell 
University) was tested for reactivity and specificity with the equine CD14 cell surface 
molecule.  Whole blood (30 mL) was collected from two horses for antibody 
validation of reactivity.  Blood samples were drawn into preservative free heparin to a 
final concentration of 33 units/mL.  The blood was processed prior to flow cytometry 
analysis using density gradient centrifugation to remove the majority of red blood cells 
as previously described [19].  Isolated peripheral blood cells were analyzed to evaluate 
reactivity of the antibody with neutrophil, lymphocyte, and monocyte populations as 
assessed by flow cytometry.  For CD14 specificity analysis, whole cell lysates were 
prepared from fresh peripheral blood leukocytes and from red blood cells with 
platelets from two additional horses.  Immunoprecipitations followed by Western blot 
analysis were performed to determine if the CD14 antibody bound a protein of the 
expected size (40kDa) based on previous literature, protein size similarity to other 
species, or predicted equine sequences.  A 15% SDS-PAGE gel was used to resolve 
the immunoprecipitated products.  Following protein transfer, the PVDF membrane 
was probed with an antibody known to recognize human CD14 (mouse anti-human 
CD14, clone biG 10, Biometec, Griefswald, Germany) in Western blot analysis.  
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Subsequently, cell surface expression of CD14 and a panel of previously validated 
antibodies were analyzed in uncultured bone marrow cells using flow cytometry 
(n=12).  Following 2 hours of culture, both adherent and non-adherent fractions of 
bone marrow cells were harvested and compared to freshly isolated bone marrow cells 
using flow cytometry (n=5).  Bone marrow cells were cultured and adherent cells were 
harvested on 2, 7, 14, 21, and 30 days for analysis of cell surface protein and gene 
expression (n=7).  In a later experiment, bone marrow cells were isolated, cultured and 
harvested for magnetic activated cell sorting (MACS) at 2 days of culture (n=6).  Cells 
from the three groups (unsorted, CD14 positive, or CD14 negatively selected) were 
returned to culture at a plating density of 20,000 cells/cm2.  Colony formation was 
assessed at day seven of culture and compared between groups.  A colony was defined 
as a cluster of fifty or more cells.  Responsiveness of MPCs to LPS stimulation (0, 1, 
5, 10 ng/mL of media) in a sample cultured 21 days and sensitivity to trypsin (n=4) 
were tested in established MPC cultures (21 days or more) and assessed by flow 
cytometry and RT-qPCR.  All procedures were performed in compliance with 
institutional guidelines for research on animals. 
Bone marrow aspirate collection and cell isolation: Cells from bone marrow 
aspirate were used to assess changes in CD14 expression over time.  Bone marrow 
aspirate was withdrawn from the sternabrae of twelve horses (6 males and 6 females, 
age range 6 months - 20 years) under standing sedation with xylazine hydrochloride 
(0.55 mg/kg IV) and local anesthesia using 2% lidocaine hydrochloride (10 mL/site).  
Samples were collected in preservative free heparin (American Pharmaceutical 
Partners Inc, Schaumburg, IL) to a final concentration of 33 units/mL.    
Aspirate (60 mL) from each horse was diluted to 180 mL total volume using 
phosphate buffered saline + 0.5% bovine serum albumin (PBS +BSA).  The white 
blood cell fraction of the sample was enriched and the majority of red blood cells were 
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removed by layering each 30 mL aliquot of dilute sample on Ficoll-Paque Plus 
(Amersham Biosciences, Piscataway, NJ) for density gradient centrifugation, as 
described for antibody validation.  Samples were resuspended in 50 mL MPC culture 
media (see below) prior to cell counting using a hemocytometer.  Approximately 2-9 x 
108 bone marrow mononuclear cells (BMMNC) were obtained per sample using this 
method.  A portion (~10 x 106 cells) of the uncultured bone marrow aspirate samples 
from all twelve horses were analyzed using flow cytometry.   
Samples from some horses (n=5) were used only for antibody validation and 
were not cultured.  The remaining samples (n=7) were subsequently cultured as 
described below.  Later, bone marrow aspirates from an additional six horses were 
processed as described above, cultured for 2 days, and utilized for MACS cell 
separation with the CD14 antibody and subsequent quantification of colony formation, 
flow cytometry, and RT-qPCR analysis.     
MPC expansion in culture: BMMNCs were plated onto 10 cm diameter tissue 
culture plates at a density of approximately 300,000 cells/cm2 (20 x 106 cells/plate).  
Cells were cultured at 37°C in a 5% CO2, 95% air atmosphere at 5% humidity.  Cells 
were cultured in media containing Dulbecco’s Modified Eagle’s medium (DMEM, 
glucose at 1000 mg/L), 2mM L-glutamine, penicillin (100 units/mL), streptomycin 
(100 units/mL), basic fibroblastic growth factor (bFGF, 1 ng/mL) and 10% fetal 
bovine serum.  One-half of the media (5 mL) was removed at 24 hours of culture and 
replaced with fresh media.  Subsequently, media were exchanged every 72-96 hours.  
At sub-confluence of 70-90%, cells were passaged 1:3 using Accumax® cell 
dissociation solution (Innovative Cell Technologies Inc, San Diego, CA) and plated at 
a density of 6,000-10,000 cells/cm2.  Approximately 10 x 106 cells from each sample 
was analyzed by flow cytometry for cell surface protein expression at two hours and 
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on days 2, 5, 7, 14, 21 and 30 of culture.  Cells were analyzed at these time points to 
evaluate the changes in cell surface proteins over time.  
Flow cytometry analysis: Cells were pelleted in aliquots containing 1 x 106 cells and 
labeled for CD14 and other cell surface molecules known to vary in expression on 
bone marrow cells over time in culture using monoclonal antibodies from a panel 
previously validated for the horse [20].  Cells were treated with a twenty minute 
blocking step using 10% normal goat serum in FACS-Buffer (phosphate buffered 
saline containing 2.5% fetal bovine serum).  The cells were pelleted, washed with 
FACS-Buffer and pelleted again.  Cell pellets were resuspended in unconjugated 
primary monoclonal antibody and incubated for 45 minutes at 4°C.  Cells were then 
washed, a second fluorescent-conjugated goat anti-mouse IgG or IgM antibody 
[Fluorescein isothiocyanate (FITC) conjugated AffiniPure Goat Anti-Mouse IgG 
(H+L) or IgM µ Chain Specific, Jackson ImmunoResearch Laboratories, Inc. West 
Grove, PA] was applied to the unconjugated primary antibodies, and the samples were 
incubated for an additional 45 minutes at 4°C.  All primary monoclonal antibodies 
were labeled with FITC-conjugated secondary antibody (read at FL1).  Cells were 
resuspended in FACS-Buffer and analyzed on a FACSCalibur (Becton Dickinson 
Immunocytometry Systems, San Jose, CA) flow cytometer equipped with a 488µm 
argon laser and BD Cell Quest™ analysis software (BD Biosciences, San Jose, CA).  
Cells not treated with antibody, and cells exposed to mouse anti-parvovirus antibody 
and FITC secondary antibodies were used as negative controls.  The settings for the 
flow cytometric analyses determined less than 2% positive cells for the control 
antibodies.  Data was collected on 1x105 cells for each sample regardless of size and 
granularity to prevent bias in gating.   
For culture expanded cells, flow cytometric analysis was performed on days 2, 
7, 14, 21, and 30 following isolation.  Supernatant was removed and adherent cells 
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were lifted from the plate using Accumax® solution (1 mL/15cm2) to prevent damage 
to cell surface proteins and avoid cellular clumping.  Cells were processed and 
analyzed by flow cytometry as described above, except dot plot settings were adjusted 
to a logarithmic scale in the cultured cells to include large, granular cells.  Flow 
cytometric analysis of cell surface molecule expression was performed in the gate 
determined to contain dividing cells based on the results from the propidium iodide 
DNA staining assay as previously described [20]. 
RNA extraction and One-Step Reverse Transcription and Quantitative 
Polymerase Chain Reaction (RT-qPCR):  Gene expression analysis was included to 
confirm negative protein results and account for kinetic changes in transcription and 
translation.  At the same time points (with the exception of the fresh and two hour 
samples) when cells were analyzed by flow cytometry, RNA was extracted from 
approximately 1-3 x 106 cells of the corresponding samples using either Trizol® (Life 
Technologies, Invitrogen, Carlsbad, CA) or the 5 Prime Perfect Pure RNA® 
extraction kit (5 Prime Inc, Gaithersburg, MD) according to the manufacturers’ 
directions.  RT-qPCR was performed to provide supporting evidence that CD14 gene 
expression levels were consistent with cell surface CD14 protein expression at the 
different time points and later following stimulation of MPCs with LPS.  CD14 gene 
expression was also compared between MPC sorted cells harvested with trypsin or 
Accumax® solutions to confirm CD14 gene expression in these samples was 
consistent with other MPC samples cultured for a similar time period.  RNA quantity 
and quality were determined using a Nanodrop® spectrophotometer (NanoDrop 
Technologies, Inc, Wilmington, DE), and visualization of 18 and 28S bands on 0.8% 
agarose gels.  A portion of the CD14 gene was cloned and agreed with previously 
reported data (AF200416).   
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Total RNA was reverse transcribed and amplified using the One-Step RT-PCR 
technique and the ABI PRISM 7900 HT Sequence Detection System (Applied 
Biosystems, Foster City, CA).  The primers and dual-labeled fluorescent probe [6-
FAM as the 5’ label (reporter dye) and TAMRA as the 3’ label (quenching dye)] were 
designed using Primer Express Software Version 2.0b8a (Applied Biosystems, Foster 
City, CA).  The CD14 probe and primers were designed using equine specific 
sequences published in Genbank, and sequenced in our laboratory.  The 18S ribosomal 
subunit was used to normalize gene expression. The 2-ddCt method was used for 
statistical analysis.  A sample from unsorted bone marrow cells cultured 14 days was 
used as the calibration sample.  The 18S gene had the following primers and probe: 
Forward 5’-CGGCTTTGGTGACTCTAGATAACC-3’; Probe FAM (5’)-CCATGGT 
AGGCACAGCGACTA-TAMRA (3’); and Reverse 5’-TCGAACGTCTGCCCTATC 
AACTTTCGAT-3’.  CD14 had the following primers and probe: Forward 5’-
TACGTGCGCTCGGGTACTC-3’; Probe FAM (5’)-CGCCTCAAGGAACTGACGC 
TGGA-TAMRA (3’); Reverse 5’-CATCGTGCCGGTTACCTCTAG-3’.   
Magnetic activated cell sorting:  Bone marrow aspirate was collected from six 
horses and processed as described above.  Following mononuclear cell isolation, bone 
marrow cells were cultured 48 hours using routine expansion conditions.  At 48 hours, 
the plates were washed twice with 5 mL of media to remove nearly all non-adherent 
cells prior to harvest using Accumax® cell dissociation solution (1 mL/15cm2).  
Adherent cells were consolidated and resuspended in 500 μL of chilled and degassed 
MACS buffer which was composed of 0.5% bovine serum albumin in phosphate 
buffered saline with 2 mmol EDTA to prevent clumping.  To remove any cell clumps 
prior to antibody labeling, samples were gravity filtered over MACS® pre-separation 
filters (Miltenyi Biotec, Inc, Auburn, CA).  Following a cell count, approximately one-
third of the sample was removed as the unsorted fraction for RNA extraction, flow 
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cytometry and culture.  The remaining two-thirds of the sample was pelleted and 
resuspended in MACS buffer and mouse anti-equine CD14 antibody (90 μL buffer + 
10 μL of antibody/107 cells), as this is the dilution used for flow cytometry.  The 
primary antibody was incubated with cells for 10 minutes at 4°C.  The labeled samples 
were washed twice with 2 mL of MACS buffer/107 cells followed by 5 minute 
centrifugations at 500 x g. Next, cell pellets were resuspended in 80 μL MACS buffer 
+ 20 μL of rat anti-mouse IgG MACS microbeads /107 cells.  Samples were incubated 
for 15 minutes at 4°C and then were washed with 2 mL of MACS buffer/107 cells 
followed by 5 minute centrifugation at 500 x g.  The column, fit with a new pre-
separation filter, was placed in the magnetic field and primed using 3 mL of chilled, 
degassed MACS buffer.  A 20 gauge needle was affixed to the end of the column to 
slow flow of liquid through the column and prevent washout of positive cells.  The 
pellet was resuspended in 500 μL of MACS buffer and placed over the primed pre-
separation filter and column.  The CD14 negative fraction was collected as the flow-
through portion of the sample.  The column was allowed to drain until the flow-
through stopped dripping between all steps.  Three washings with 3 mL of MACS 
buffer each were used to rinse additional negative cells from the column.  The CD14 
positive fraction of the sample was collected following removal of the column from 
the magnetic field.  The column was loaded with 5 mL of MACS buffer and a plunger 
was used to force positive cells from the column into a collection tube.  Positive and 
negative fractions were counted and the samples divided for RNA extraction, flow 
cytometry analysis, and culture as described above for the unsorted fraction. 
Flow cytometry to assess sort purity: For the unsorted fraction, approximately 6 x 
106 cells were collected for flow cytometry analysis using a previously validated panel 
of monoclonal antibodies and the CD14 antibody as previously described (see Flow 
cytometry analysis; page 87).  The positive and negative sorted fractions had 2 x 106 
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cells allocated for flow cytometry analysis. 1 x 106 cells of each sorted fraction 
remained unlabeled with fluorescent secondary, the other 1 x 106 cells were labeled 
with goat anti-mouse IgG FITC secondary antibody and analyzed as previously 
described.  
Colony formation assay: For all three fractions (CD14 positive, CD14 negative, and 
unsorted) 1.15 x 106 cells were collected for quantitative analysis of colony formation 
following one week of culture.  A plating density of 20,000/cm2 in 6 well plates was 
used.  Routine culture commenced as described above.  On day 7 of total culture 
(since bone marrow aspiration) the numbers of colonies present in each fraction were 
counted.  A colony was defined as a cluster of 50 or more fibroblastic cells.  Colony 
numbers were compared between the unsorted and CD14 positively and negatively 
selected fractions. 
CD14 gene expression analysis between CD14 sorted and unsorted cells over 
time: CD14 gene expression data was compared over time between unsorted, positive 
and negative selected cells using the 2-ddCt method with an unsorted bone marrow 
sample cultured 14 days used for the calibrator sample as described above.  The first 
time point when sufficient MPC numbers were available in three fractions was 14 days 
of culture for at least half of the horses (n=3), later time points had sufficient MPC 
numbers for all horses (n=6).   
Analysis of CD14 expression in cultured MPCs in response to LPS stimulation: 
Bone marrow cells from one horse were isolated, cultured and MACS sorted as 
described above.  At 21 days, a portion of the CD14 positive fraction and the unsorted 
fraction were incubated overnight with LPS (026:B6, L2762; Sigma-Aldrich, Saint 
Louis, MO) at varying dosages (0, 1, 5, or 10 ng/mL media).  Samples of treated and 
control cells were collected for flow cytometry analysis of CD14 protein expression 
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and RNA extraction for RT-qPCR analysis of CD14 gene expression.  Assays on 
samples were performed as described above. 
Analysis of cell surface marker expression in response to trypsinization: Bone 
marrow cells from four horses were isolated, cultured and MACS sorted as described 
above.  At 30 days of culture, approximately 10 x 106 cells from each fraction (CD14 
positive, CD14 negative or unsorted) were harvested using Accumax® cell 
dissociation solution as previously described.  An additional 10 x 106 cells from each 
fraction were harvested following five minutes of incubation at 37°C using 0.25% 
trypsin in Hanks Balanced Salt Solution (HBSS) with divalent cations.  2 x 106 cells 
from each sample were used for RNA extraction and subsequent RT-qPCR (to verify 
CD14 expression was present at comparable expression levels between fractions).  
The remaining 8 x 106 cells were used for flow cytometry analysis with the same panel 
of antibody markers as previously described. 
Statistical analysis: Gene expression data for the initial unsorted cells were 
categorized into four groups by culture duration: 1=less than one week; 2=one week; 
3=two weeks; 4=three weeks or more.  Colony formation data were categorized into 
three groups by cell sorted fraction: 1= unsorted; 2=CD14 positive; 3=CD14 negative 
(data was blocked by horse).  The gene expression data for analysis of sorted versus 
unsorted cells were categorized by culture duration: 1=two weeks; 2= three weeks; 3= 
four or more weeks.  LPS cell stimulation data were categorized by cell fraction 1= 
unsorted; 2= CD14 positive, and LPS dose: 1= 0 ng/mL; 2= 1, 5, or 10 ng/mL LPS.  A 
One-Way ANOVA, blocked by horse and Tukey’s All-Pairwise Comparisons post hoc 
was used to compare the percentage of positive cells as assessed by flow cytometry 
between cell dissociation solutions (1=Accumax; 2=trypsin).  The 2-ddCt method was 
used for statistical analysis of CD14 gene expression.  The 18S gene was used to 
normalize gene expression.  Groups were compared using a One-Way ANOVA with a 
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Tukey All-Pairwise Comparisons post hoc test.  A p-value of <0.05 was considered 
significant.   
 
Results 
Validation of antibody binding to the CD14 molecule on equine peripheral blood 
cells: Equine CD14 antibody was confirmed reactive to equine molecules on blood 
cells as assessed by flow cytometry analysis (Figure 3.1).  There was low mean 
fluorescence intensity detected for CD14 in the neutrophil population (Figure 3.1, B1) 
and high mean fluorescence intensity in the monocyte population (Figure 3.1, B3) as 
expected.  A small population of cells in the lymphocyte gate (Figure 3.1, B2) had 
low mean fluorescence intensity which likely represent the activate B lymphocyte 
population; however double labeling would be required to confirm that these cells are 
B lymphocytes. 
Validation of CD14 specificity in equine peripheral blood cells: Western blot 
analysis alone did not clearly determine specificity of the CD14 antibody reaction with 
equine blood cells.  No distinct band was detected on multiple attempts to analyze 
CD14 antibody binding.  It was proposed that this antibody might not recognize the 
denatured protein.  The BiG10 antibody (catalog #021-1c.2, Biometec, Greifswald, 
Germany) has been extensively used for immunoprecipitation in human cells.  
Immunoprecipitation using the mouse anti-equine CD14 antibody (clone 105) 
followed by Western blot analysis with the BiG10 antibody confirmed the CD14 
antibody (clone 105) reacted with a single protein of approximately 40kDa (Figure 
3.2).  
Flow cytometric analysis of cell surface marker expression in bone marrow cells 
freshly isolated and cultured for two hours:  There were no discernable differences 
in mean fluorescence intensity between freshly isolated cells and cells which were 
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Figure 3.1 Flow cytometric analyses of cell surface molecule expression of CD14 in 
freshly isolated peripheral blood cells. Dot plot distribution of uncultured peripheral 
blood cells isolated using A1) gradient density centrifugation or A2) carbonyl iron 
incubation followed by gradient density centrifugation.  B1-B3) Histogram analysis of 
mean fluorescence intensity of CD14 cell surface molecule expression in the gated 
areas (Regions 1, 2, and 3, respectively, for isolated peripheral blood cells).  The R1 
gate corresponds to the size and granularity of neutrophils from A1; R2 lymphocytes 
from A2; R3 monocytes from A2; the shaded curves represent negative isotype control 
staining.  Open lines represent the mean fluorescence intensity for CD14.  Note that 
neutrophils (B1) have low mean fluorescence intensity for CD14 expression while 
monocytes (B3) have high mean fluorescence intensity.  The small population of 
lymphocytes (B2*) which have low mean fluorescence intensity, likely represent the 
activated B lymphocyte population; however, double labeling would be required to 
confirm that these are B lymphocytes. 
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Figure 3.2 Western blot analyses to test the specificity of CD14 antibody in equine 
peripheral blood cells. A1 Western blot following immunoprecipitation using either 
anti()-equine CD14 antibody (B.Wagner, Cornell University, clone 105) or mouse 
anti-human CD14 antibody (BiG10, catalog #021-1c.2, Biometec, Greifswald, 
Germany) with equine blood cells and probing with BiG10 antibody. White blood cell 
(WBC) or red blood cell/platelet (RBC) lysates incubated with both -CD14 
antibodies retained protein bands, of approximately 40kDa (*). Arrow (→) indicates 
the heavy chain of IgG; arrowhead (►) indicates the light chain of IgG.  A2 
Molecular size standards.   
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non-adherent after two hours of culture (Figure 3.3 Parts A and B).  There was a 
slight shift in population distributions between some regions (e.g. there were slightly 
higher percentages of cells in Region 2 in non-adherent cells compared to freshly 
isolated cells).  In contrast, bone marrow cells, which were adherent following two 
hours of culture, had a unique dot pot distribution (Part C).  
There were no notable differences detected in molecule expression in Region 1 
between all markers analyzed for the three groups.  There were dramatic differences in 
cell surface expression for all CD markers analyzed on cells in Regions 2 and 3 
between freshly isolated or 2 hour non-adherent cells compared with adherent cells. 
cultured for 2 hours (Part D).  Only a small population of cells was positive for CD44 
expression in Regions 2 and 3 initially (and after two hours in the non-adherent cell 
fraction).  In contrast, after two hours of culture, the few remaining Region 2 cells and 
a large number of Region 3 adherent cells were nearly all positive for CD44.  Cells 
were brightly positive for CD90 expression for Region 1 in all three fractions, 
consistent with the expression profile of neutrophils.  Cells in Region 2 were negative 
for CD90 expression in all fractions, consistent with the expression profile of 
lymphocytes.  Most adherent cells in Region 3 were low positive in CD90 expression 
following culture and with a small population with higher levels of expression (*); this 
result is consistent with a mixture of two cell populations (the lower level would be 
more typical for the pattern of expression by monocytes and the higher mean 
fluorescent intensity is consistent with the pattern for neutrophils).  Multiple 
populations when gates include overlapping cell populations in the interfaces.  
CD11a/CD18 expression was once again bright in all three fractions for cells in 
Region 1. 
Cells in Region 2 and 3 followed a similar pattern in CD11a/CD18 expression, 
as it was discussed previously for CD44 with fresh and two hour non-adherent cells
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Figure 3.3 Flow cytometric analyses of cell surface molecule expression in freshly 
isolated bone marrow cells compared to cells cultured 2 hours. A-C) Dot plot 
distribution of bone marrow cells isolated using gradient density centrifugation 
followed by either A) fresh/uncultured analysis or analysis of the B) non-adherent or 
C) adherent cell fractions after two hours of culture.  Note that the size, granularity, 
and distribution of the adherent cell population following two hours of culture are 
different from freshly isolated and non-adherent cells.  After two hours of culture, 
cells in Region 2 were primarily non-adherent, while cells in Region 3 were primarily 
the adherent type.  D) Histogram analysis of mean fluorescence intensity of cell 
surface molecule expression in the gated areas (Regions 1, 2, and 3 respectively).  The 
shaded curves represent negative isotype control staining; open lines represent the 
labeling for the cell surface markers indicated in the left-hand side.  No notable 
differences were detected in molecule expression in Region 1 in all markers analyzed.  
There appear to be only minor differences between freshly isolated cells and cells that 
were non-adherent after two hours of culture.  Note the dramatic difference in cell 
surface expression in Regions 2 and 3 for all CD markers analyzed between freshly 
isolated or 2 hour non-adherent cells compared with cells which were adherent after 2 
hours of culture.  Short term culture of two hours can be used to separate cells with 
varying maturities based on adherence.  Cells which are non-adherent at two hours of 
culture appear to be similar in expression profile to freshly isolated bone marrow cells, 
while adherent cells possess a different expression phenotype consistent with more 
mature cells. 
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having a low number of positive cells while the adherent cells in these regions were 
nearly all brightly positive for CD11a/CD18 expression.  CD14 expression was low in 
mean fluorescence intensity for Region 1 in all three fractions, consistent with the 
pattern seen in neutrophils.  In Region 1, a small population of CD14 brightly positive 
cells was noted, again consistent with overlapping gating between neutrophil and 
monocyte populations.  Cells in Region 2 were negative for CD14 expression, 
consistent with the expression pattern of lymphocytes.  Cells in Region 3 from the 
adherent fraction were primarily brightly positive with a smaller population of low 
positive cells, consistent with the pattern that primarily monocytes were present with a 
few neutrophils also present.  CD172a expression once again was positive for all three 
groups in Region 1.  Cells in Region 2 were negative for CD172a expression, again 
consistent with the expression profile of lymphocytes.  Cells in Region 3 had very 
small populations of CD172a positive cells in fresh and non-adherent cell fractions 
while adherent cells were uniformly brightly positive. 
Flow cytometric analysis of cell surface marker expression in cultured bone 
marrow cells: After two days of culture, adherent mononuclear cells displayed an 
antibody labeling pattern of CD44hi, CD90hi, CD11a/CD18mod, CD14mod, and CD172a 
high (Figure 3.4).  In Gate 3, there appeared to be a heterogeneous cell population as 
evidenced by multiple peaks in CD44, CD90, and CD14 mean fluorescence intensity.  
On day seven, CD44 expression decreased slightly in mean fluorescence intensity, but 
remained strongly positive and became more homogenous. CD90 expression was 
negative in two of the three cell populations present, but high mean fluorescence 
intensity was noted in a third population.  Meanwhile, CD11a/CD18, CD14, and 
CD172a cell surface expression decreased, with a shift in the populations to lower 
mean fluorescence intensity.  By fourteen days, adherent cells were CD44hi, 
CD90hi/variable, CD14low, CD172alow and CD11a/CD18neg; these cells displayed a 
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Figure 3.4 Flow cytometric analyses of cell surface molecule expression in cultured 
bone marrow cells from two through twenty-one days of culture. Part A-D dot plot 
distribution of bone marrow cells cultured A, 2 days ; B, 7 days ; C 14 days ; or D 21 
days. Part E Histogram analysis of mean fluorescence intensity of cell surface 
molecule expression in the gated areas (Regions 1, 2, and 3 respectively).  The shaded 
curves represent negative isotype control staining; open lines represent the labeling for 
the cell surface markers indicated in the left-hand side.  Note that samples at 2 and 7 
days of culture have multiple populations present indicated by multiple peaks in the 
overlay histograms.  By day 14, the cell population is more homogeneous in mean 
fluorescence intensity for most markers, but remained variable for CD90 protein 
expression.  At 21 days of culture, putative MPCs were CD44hi, CD90hi, CD14low, 
CD172alow and CD11a/CD18neg with a homogenous population in all markers 
analyzed.  The mean fluorescence intensity of CD14 expression is reduced over time 
in later samples compared to mean fluorescence intensity on day 2, but continues at 
low levels throughout culture. 
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Figure 3.4 (Continued) 
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fibroblastic morphology characteristic of MPC (data not shown).  Multiple cell 
populations were noted via several peaks in CD90 mean fluorescence intensity at 14 
days, with a growing number of positive cells compared to percentages at 7 days.  All 
other markers had homogeneous protein expression by 14 days.  This pattern of 
molecule expression was retained at 21 days for all MPC samples, with CD90 
becoming homogenous with high mean fluorescence intensity.  At all time points (2, 
7, 14, and 21 days), adherent bone marrow cells in culture showed a consistent protein 
phenotype.  The only variable between horse samples was the number of days (14 or 
21) needed before the predominant cell population was homogeneous for CD90 
expression. 
Gene expression kinetics of CD14 in cultured bone marrow cells over time: CD14 
gene expression data was consistent with cell surface protein expression at all culture 
time points.  CD14 gene expression was present in all samples but became 
significantly less (P≤0.005) over time (Figure 3.5).  Samples cultured one week or 
less had significantly more CD14 expression than samples cultured more than one 
week. CD14 expression remains stable at low levels after 14 or more days of culture 
with less than one fold change compared to the control sample. 
Magnetic activated cell sorting using the mouse anti-horse CD14 antibody: Cell 
sorting of the adherent cells following two days of culture led to distinct distributions 
of cells within the positive and negative fractions compared to unsorted conditions 
following  MACS  (Figure 3.6)  as assessed by flow cytometry.  The CD14 positive 
fraction primarily concentrated cells in Region 3, while CD14 negative selection 
primarily concentrated cells in Region 2. 
Quantification of colony formation: Following a week of culture, a significant 
difference in MPC colony formation was noted between all three fractions (P≤0.005) 
(Figure 3.7).  Cells positively selected for CD14 expression had significantly more 
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Figure 3.5 Gene expression of CD14 during increasing culture durations. CD14 
expression was significantly higher in cells cultured one week or less compared to 
cells cultured more than one week (P≤0.005).  Despite a significant decrease over 
time, CD14 expression was detected in all samples.  A bone marrow sample cultured 
for 14 days was used as the control sample for comparison using the 2-ddCt method. 
Bars represent n=6 ± SE, letters denote significant differences when analyzed using 
one-way ANOVA and Tukey’s All-Pairwise Comparisons.   
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Figure 3.6 Flow cytometric dot plot analysis of equine bone marrow cells cultured for 
2 days, following MACS sorting using a mouse anti-equine CD14 antibody.  Note that 
the percentage distribution of cells in each region varies between fractions. 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Colony counts on day 7 of culture in bone marrow cells with or without 
selection using an anti-equine CD14 antibody at 2 days of culture.  The number of 
MPC colonies formed per 106 cells in each fraction were tested by one-way ANOVA, 
blocked by horse, and Tukey’s All-Pairwise Comparisons post hoc (n=6±SE). There 
were significant differences (P≤0.005) between all three groups.  Positive selection 
using an anti-equine CD14 antibody appears to enrich the putative MPC population 
over negative selection and unsorted conditions. 
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MPC colonies formed than either unsorted or negatively selected fractions, with nearly 
double the colony counts of unsorted cells and over twenty times the number of 
colonies formed in the CD14 negatively selected fractions.   
CD14 gene expression over time between sorted and unsorted cells:  There were 
no significant differences between CD14 expression in any of the three fractions at 14 
(n=3; p=0.013), 21 (n=6; p=0.87), or 30 (n=6; p=0.49) days of culture.  Many horses 
(n=3) did not have sufficient MPC cell numbers (≥ 50,000) in the negatively selected 
fraction at fourteen days for analysis.  The small sample size (n=3) at 14 days may 
have prevented detection of a significant difference between fractions.  An unsorted 
bone marrow sample which had been cultured for 14 days was used as the control 
sample for comparison using the 2-ddCt method.  Statistical analysis was performed 
using one-way ANOVA and Tukey’s All-Pairwise Comparisons.   
Flow cytometric analysis of CD14 expression in cultured MPCs in response to 
LPS stimulation: There were no detectable differences in CD14 mean fluorescence 
intensity present between unsorted and CD14 positively selected MPCs after 21 days 
of culture, with or without overnight LPS stimulation as assessed using flow 
cytometry (data not shown).  There was a detectable difference in mean fluorescence 
intensity between untreated and LPS stimulated cells in both cell fractions (Figure 
3.8).  All doses of LPS (1, 5, or 10 ng/mL media) caused an increase in both 
percentage of positive cells and CD14 mean fluorescence intensity, suggesting equine 
MPCs respond to LPS stimulation with an upregulation of CD14 protein expression. 
RT-qPCR analysis of CD14 gene expression in cultured MPCs in response to LPS 
stimulation: There were no detectable differences in CD14 expression between 
unsorted and positively selected MPCs following 21 days of culture as assessed using 
RT-qPCR.  Both fractions had similar levels of CD14 expression to control samples, 
and displayed a similar increase in CD14 expression in response to LPS stimulation 
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Figure 3.8 Flow cytometric analysis of CD14 cell surface molecule expression in 
unsorted bone marrow cells in response to LPS stimulation.  Note that cells in Region 
3 appear to be responsive to LPS stimulation, increasing both percentage of positive 
cells and mean fluorescent intensity over control conditions.  Part A. Dot plot 
distribution of unsorted bone marrow cells cultured 21 days. Part B. Histogram 
analysis of CD14 mean fluorescence intensity in Region 3 following overnight 
incubation of cells with LPS (026:B6, L2762; Sigma-Aldrich, Saint Louis, MO) of 
differing concentrations (0, 1, 5, or 10 ng/mL media).  The histograms represent cell 
surface molecule expression using either a negative isotype control antibody (left 
column) or the mouse anti-equine CD14 antibody with FITC conjugated IgG 
secondary antibody (right column).  M1 represents the setting used for negative cell 
percentage calculations based on isotype control labeling.  M2 represents the setting 
for positive cell percentage calculations.  (LPS, lipopolysaccharide; MFI, mean 
fluorescence intensity) 
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(Figure 3.9).  Analysis of 2-ddCt demonstrates a significant difference in CD14 
expression between untreated and LPS stimulated cells in both fractions (p≤ 0.005).   
culture time point (e.g. 2 days of culture) in order to determine if the CD11a/CD18 
epitope is trypsin labile.  The low mean fluorescence intensity of CD14 expression.  
Cells treated with any dose of LPS (1, 5, or 10 ng/mL media) had a 2.24 (±0.12) fold 
increase in CD14 expression over untreated cells (Figure 3.9). Both unsorted and 
CD14 positive selected MPCs respond to LPS stimulation with an up regulation of 
CD14 expression, supporting the flow cytometry data. 
Analysis of cell surface marker expression in response to trypsinization: Flow 
cytometric data demonstrated no detectable difference between sorted and unsorted 
fractions in cells cultured 30 days for all cell surface molecules tested (Figure 3.10).  
MPCs in all fractions (unsorted, CD14 positive, or CD14 negatively selected) were 
CD44hi, CD90hi, CD11a/CD18neg, CD14low, and CD172alow in phenotype, similar to 
initial bone marrow flow cytometry results described previously when cells were 
harvested using Accumax® cell dissociation solution.  Following harvest using 0.25% 
trypsin in HBSS, there was a change in phenotype in all fractions to CD44low, CD90hi, 
CD11a/CD18neg, CD14neg, and CD172alow.  Statistical analysis of flow cytometry data 
demonstrates significant drops (P≤0.005) in percentages of positive cells following 
cell harvest using trypsin versus Accumax® cell dissociation solution (Figure 3.11) in 
several protein markers.  The mean fluorescence intensity for CD44 was decreased in 
all samples when trypsin was used for cell harvest, but expression was still present. 
The percentage of CD44 positive cells dropped from 98.05% (±4.09) to 39.98% 
(±4.56) when trypsin was used for cell harvest.  There appears to be no effect on 
CD90 mean fluorescence intensity when trypsin in used for cell harvest, with no 
difference in the percentages of positive cells between treatments.  CD11a/CD18 had a  
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Figure 3. 9 Gene expression kinetics of CD14 in equine bone marrow cells which were unsorted or CD14 positive selected (at two 
days of culture).  MPCs were subsequently cultured 21 days and treated with LPS (026:B6, L2762; Sigma-Aldrich, Saint Louis, 
MO) at dosages of 0, 1, 5, or 10 ng/mL media.  Part A 18S gene amplification plot verifies equal loading of RNA between control 
and treated samples.  Part B CD14 amplification plot of LPS stimulated and control bone marrow cells.  Putative MPCs treated 
with 0 ng/mL of LPS (←) had higher Ct values (therefore lower levels of CD14 expression) than cells which were treated with 
LPS in any dose (►).  By 21 days there is no detectable difference in CD14 expression between the CD14 positive selected and 
unsorted cells within the control and LPS stimulated groups.  Both groups respond to LPS stimulation with an upregulation of 
CD14 expression, supporting the previous flow cytometry data.  Analysis of 2-ddCt demonstrates a significant difference (P≤0.005) 
with LPS treated cells showing a 2.24 (±0.12) fold increase in CD14 expression over untreated cells. (LPS, lipopolysaccharide)  
←► 
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Figure 3.10 Flow cytometric analysis of cell surface molecule expression in sorted 
and unsorted bone marrow cells cultured 30 days.  Parts A & B. Dot plot distribution 
of bone marrow cells from the respective fractions following MACS sorting using an 
anti-equine CD14 antibody at 48 hours of culture, and subsequent culture until 30 
days. Adherent cells were collected for analysis following five minutes of incubation 
at 37°C with either Accumax® cell detachment solution (Part A) or 0.25% trypsin in 
HBSS (Part B). Part C. Histogram analysis of mean fluorescence intensity of cell 
surface molecule expression in the gated area (Region 3).  Shaded curves represent 
negative isotype control staining; open lines represent labeling for the cell surface 
markers indicated on the left-hand side.  Note the similarity in protein expression 
between the unsorted, positive, and negative fractions when Accumax® cell 
detachment solution is used, suggesting the cells in each fraction are phenotypically 
similar at the 30 day time point.  When trypsin is used to collect the cells for analysis, 
note the decrease in mean fluorescence intensity for CD44 and CD172a and the 
absence of mean fluorescence intensity for the CD14 sample compared to the isotype 
control, suggesting these epitopes are trypsin labile.   The positive and negative sorted 
fractions showed a similar pattern of decrease in CD44, CD172a and CD14 protein 
expression when cells were collected using trypsin (data not shown) compared to the 
unsorted fraction shown in Part C (rightmost column).  CD90 did not change in mean 
fluorescence intensity and did not appear to be affected by trypsin.  The effect of 
trypsin on CD11a/CD18 expression could not be determined using a 30 day cultured 
sample since protein expression levels of this marker were low in all groups. 
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Figure 3.10 (Continued) 
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Figure 3.11 Flow cytometric analysis of cell surface molecule expression in bone 
marrow cells cultured 30 days and lifted following 5 minutes of incubation at 37°C 
with either Accumax® or 0.25% Trypsin in HBSS.  The percentage of positive cells 
using the respective antibody was compared between solutions, and tested by One-
Way ANOVA, blocked by horse, and Tukey’s All-Pairwise Comparisons post hoc 
(n=4 ± SE).  There were significant differences (P ≤ 0.005) in positive percentages of 
CD44, CD14, and CD172a expression (*) when trypsin was used instead of 
Accumax® for cell preparation.  There was no significant difference in positive 
percentage of CD90 expression between cell lifting solutions.  The overall percentage 
of positive cells using CD11/CD18 antibody was very low in both treatment groups, 
making comparison between solutions difficult at this time point in culture (no 
significant difference was detected).  Lifting cells with a 0.25% Trypsin solution for 
flow cytometric analysis reduces the detection of some but not all cell surface 
markers. 
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trend (P=0.06) toward decreased percentages of positive cells, but the low percentages 
of positive cells in both treatments do not allow for any conclusions to be drawn on 
the effect of trypsinization.  Bone marrow cells would need to be tested at an earlier 
time point to determine if the CD11a/CD18 epitope is trypsin labile. The low mean 
fluorescence intensity of CD14 disappeared following trypsinization compared to cells 
that were harvested using Accumax®, suggesting that the CD14 epitope is trypsin 
labile.  The percentage of CD14 positive cells was significantly reduced from 27.60% 
(±2.61) to 3.18% (±2.92) following incubation with trypsin, causing the trypsin treated 
samples to appear negative for CD14 expression, suggesting that the CD14 epitope is 
trypsin labile.  A decrease in mean fluorescence intensity for CD172a was also noted 
in all fractions when trypsin was used for cell harvest.  There was a significant drop in 
CD172a percentages from 63.39% (±4.89) to 8.08% (±5.18) when trypsin was used 
for cell harvest.  Harvesting cells for flow cytometry analysis with trypsin appears to 
damage several cell surface proteins, while others appear to be unaffected.  CD14 gene 
expression analysis of cells used in the comparison between trypsin and Accumax® 
cell harvest solutions demonstrated a low level of CD14 gene was present in all 
samples at levels (data not shown) comparable to 30 day cultured MPC data presented 
above.   
 
Discussion 
In this study, temporal changes in protein and gene expression of the cell 
surface marker CD14 in bone marrow cells were demonstrated.  Comparison of 
freshly isolated bone marrow cells with cells that were primarily adherent or non-
adherent after two hours of culture showed distinct differences in CD14 and other cell 
surface marker proteins between fractions.  The mean fluorescent intensity of CD14 
expression and the percentages of CD14 positive cells were much higher in the 
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adherent monocyte-sized population when compared to cells that were monocyte-sized 
from the freshly isolated or non-adherent fractions (Figure 3.3, R3).   
 Most adherent cells following two hours of culture would be expected to be 
granulocyte (Figure 3.3, R1) or monocyte lineages (Figure 3.3, R3), with few 
lymphocytes (Figure 3.3, R2) present.  Culture of two hours duration appears to be 
useful in separating bone marrow cells types with varying properties based on 
adherence.  Cells which were non-adherent at two hours of culture appear to be similar 
in expression profile to freshly isolated cells, while adherent cells possess a different 
expression phenotype, consistent with adherent hematopoietic cells.  These results 
suggest that separation of freshly isolated bone marrow cells may lead to inaccurate 
classification of hematopoietic versus non-hematopoietic cells.  Freshly isolated 
hematopoietic cells may not express cell surface proteins (e.g. CD11a/CD18 or CD14) 
normally associated with their hematopoietic lineage, leading to contamination of the 
true non-hematopoietic population with hematopoietic cells.  Caution should be 
exercised when evaluating results of studies that attempt to sort hematopoietic from 
non-hematopoietic cells using uncultured bone marrow samples. 
One of the defining features of MPCs in humans and other species is lack of 
expression of the CD14 epitope, also known as the lipopolysaccharide receptor (LPS-
R) on their cell surface.  However, I have demonstrated that CD14 is expressed on the 
surface of putative equine MPCs and can be used as a marker to enrich for the MPC 
population.  Mean fluorescence intensity and CD14 gene expression decrease 
significantly in established MPC populations compared to cells cultured seven days or 
less; however after 14 days of culture, CD14 expression at both the protein and gene 
level was stable.  This is in contrast to cell surface markers such as CD11a/CD18, 
which were negative in equine MPCs cultured 14 or more days.  All RNA samples 
analyzed by RT-qPCR were able to reach a Ct value for CD14 expression, unlike 
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CD11a and CD45 in a previous study [20], suggesting that CD14 expression is present 
in equine MPCs. 
 MACS using an anti-equine CD14 antibody was successful in enriching MPC 
colony formation in the CD14 positive fraction compared to unsorted and negatively 
selected fractions.  The procedure was relatively easy to perform; however, several 
factors are required to use this technique successfully. You must choose an epitope 
which is present in sufficient quantities on the cell surface of the positive population 
(so they will be retained in the column), but not the negative population (so they will 
flow-through the column) or you will not concentrate the desired cell type.  A primary 
antibody that can be strongly bound by the secondary microbeads is also essential for 
successful MACS.  Care is needed to avoid overloading the column with excessive 
numbers of cells, otherwise positive cells will leak into the negative fraction.  Not 
every antibody works well in the MACS application and I was fortunate to have the 
anti-equine CD14 antibody provided. Preliminary work using the BiG10 anti-human 
CD14 antibody for MACS of equine bone marrow cells led to similar overall results 
with many more MPC colonies in the positive versus negative fractions, with a distinct 
separation of approximately ten times (versus over twenty times using the anti-equine 
antibody) in the number of colonies in the positive fraction compared to the negative 
fraction (data not shown).  
 Flow cytometry was useful in the assessment of purity of sorted cells using 
MACS.  Previous work from our laboratory [20] suggests that MPCs come from the 
region concentrated in the CD14 positive fraction (R3) as shown in Figure 3.6.  The 
percentage of positively selected cells located in this region was nearly double the 
percentage of unsorted cells, and 3-5 times more than the negatively selected cell 
fraction.  Comparison of percentages in cell distribution between cell fractions helps 
confirm an initial difference between the unsorted and sorted fractions. 
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 Contrary to my hypothesis, the MPC population was not enriched in the CD14 
negative fraction of equine bone marrow cells. Putative MPC colonies were enriched 
in the CD14 positive fraction approximately two-fold over unsorted, and more than 
twenty-fold over negatively selected cells at day seven of culture (Figure 3.7). These 
results suggest that equine MPCs are not CD14 negative as reported in other species.    
CD14 gene expression between unsorted and sorted cells was not different in 
cells cultured 14 days or more.  However, half of the samples from the MACS sorting 
experiment (n=3) did not have sufficient MPC cell numbers in the negatively selected 
fraction to rule out the possibility that a difference in CD14 expression exists.  More 
sorted samples cultured 14 days will need to be prepared to confirm that the lack of a 
significant difference in CD14 expression is real.  By 21 days, MPCs from each 
fraction appear to have equivalent CD14 expression, suggesting that the MPCs 
growing in all three fractions are the same cells.  The difference between fractions 
appears to be the quantity of MPCs available for analysis at early time points (e.g. at 
14 days, few MPCs were present in the negative fraction in all samples; only half of 
the negative samples had ≥ 50,000 cells, sufficient for RNA extraction).   RNA 
samples from the 48 hour MACS separation are still awaiting analysis and will answer 
the questions whether an initial difference in CD14 expression exist between the 
fractions.  If a difference in CD14 expression is detected, it will provide additional 
supporting evidence of purity of MACS sorted cells. 
 CD14 protein and gene expression were both upregulated in equine MPCs 
following stimulation by LPS.  Cells outside of the hematopoietic lineage should not 
be capable of responding to LPS stimulation when isolated from cells that normally 
express CD14 on their cell surface (e.g. myeloid cells such as monocytes, dendritic 
cells, and neutrophils).  Therefore, either hematopoietic cells, such as monocytes and 
dendritic cells, are still present in MPC cultures at 21 days (stimulating CD14 
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expression in MPCs through secretion of the soluble form of CD14) or cultured MPCs 
do have low levels of CD14 expression on their cell surface and are directly 
responding to LPS.  If the latter is true, the non-hematopoietic lineage of equine MPCs 
must be questioned.   
 In humans and other species, MPCs are reported to be negative for CD14 
protein expression as assessed by flow cytometry.  However, many studies consider 
CD14 negative, even though they report low levels of CD14 expression.  For example, 
a recent MPC characterization study performed in sheep reported 28.5% (±13.8) of 
cultured MPCs were positive for CD14 expression at passages 3 and 4, but still 
classified the ovine cells as CD14 negative [21].  The percentage of positive ovine 
MPCs in that study may have also been artificially lowered since trypsin was used for 
cell harvest prior to flow cytometric analysis.   
In the original characterization paper by Pittenger et al., CD14 expression was 
reported as negative in human MPCs [6].  In that study, cells were harvested using 
either trypsin or EDTA, with no reported difference in cell surface protein detection 
for any marker between cell dissociation solutions.  Most subsequent MPC 
characterization studies have used the protocol described by Pittenger, including 
trypsinization, for cell harvest prior to flow cytometry analysis.  I have clearly 
demonstrated that equine MPCs had a low mean fluorescence intensity of CD14 
detection when cells were lifted with Accumax® cell dissociation solution. When 
trypsin was used instead, CD14 expression was no longer detected in samples from the 
same MPC fractions.  My data suggest that CD14 is a trypsin labile protein in the 
horse.  Some cell surface proteins were also found to be trypsin labile including CD44 
and CD172a, while others such as CD90 had no detectable sensitivity to trypsin.  
Given these findings, the use of trypsin prior to flow cytometry analysis in equine 
bone marrow cells is not recommended. 
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My results suggest that equine MPCs are enriched by selection for CD14 
protein expression.  Equine MPCs also appear to have long term expression of CD14 
protein in cultured cells, which can be upregulated by stimulation with LPS, and 
damaged by exposure to trypsin, making them appear falsely negative for CD14.  A 
plausible conclusion from these findings is that equine MPCs are derived from a CD14 
positive precursor cell.  Cells of stromal origin should not be CD14 positive, 
suggesting that equine putative MPCs do not fit the typical classification of stromal 
cells.  My data supports the premise that equine MPCs are more likely derived from a 
hematopoietic precursor.  In the future, I hope to further evaluate the potential role of 
MPCs in tissue regenerative therapeutic and research applications.   
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CHAPTER 4 
 
SUMMARY AND CONCLUSIONS BASED ON EXPERIMENTAL RESULTS 
 
What is the True Lineage of Mesenchymal Progenitors in the Horse?  
Classically, MPCs have been defined and characterized as non-hematopoietic 
in origin.  The reasons behind this assumption include the highly proliferative 
behavior of these cells in culture, their response to in vitro “differentiation”, and their 
lack of expression of certain cell surface proteins thought to be characteristic of 
hematopoietic cells.  At this time, my results question the assertions that MPCs 
represent “true” mesenchymal stem cells and that they arise from a non-hematopoietic 
origin.   
 As much as MPCs differ from hematopoietic cells in certain cell surface 
characteristics, they also do not share many properties of “stem cells”.  For example, 
MPCs cannot self renew long term, and typically can be culture expanded for only a 
few weeks before their proliferation slows.  Rat MPCs cultures have been shown to 
undergo senescence during the first 30 days in culture,  with an increase in population 
doubling time, decreased DNA repair, and loss of telomerase activity [1]. It has been 
proposed that human MPCs enter senescence as soon as they are placed into culture 
[2].  The average population doubling of human MPCs derived from bone marrow is 
reported as 38±4 times [3], which means the total lifespan of these cells in culture is 
limited to a timeframe of a few months.  A true stem cell divides infrequently and 
should be able to self renew for the lifetime of the organism, so clearly cultured MPCs 
do not meet the strict definition of “stemness”.   
Not only do MPCs lose their ability to rapidly proliferate with long term 
culture, they also appear to lose their “differentiation” and therapeutic potential over 
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time.  Previous studies have shown the in vitro differentiation potential of MPCs in 
humans and other species decreased above passage 30 in osteogenic and adipogenic 
assays, while telomere length in these cells decreased over time [2-4].  Long term 
culture also appears to decrease the supportive activity that MPCs can provide for 
hematopoiesis [5].  Early passages of MPCs were able to promote CD34+ HSC 
engraftment when co-injected into SCID mice, but beyond passage 9, MPCs were 
unable to promote HSC engraftment [5].  In addition, MPCs have other potential 
therapeutic effects which have been shown to decrease with extended culture.  In one 
study, cultured murine MPCs were placed into areas of damage in rat hearts.  The 
murine MPCs lost their protective effects as the culture expansion times before 
implantation increased from passage 3 to passages 5 and 10.  The recipients who 
received later passage cells had subsequent lack of improved cardiac function 
compared to rats who received passage 3 cells [6].  Extensive expansion of MPCs 
appears to decrease their therapeutic usefulness, so most studies recommend limiting 
ex vivo culture to minimize any potential loss of efficacy. 
Another problem in classifying MPCs is that the minimal criterion used to 
define human MPCs does not clarify if the cell surface phenotype refers only to 
established MPC cultures, or if cells must have the same protein phenotype from 
initial isolation throughout culture [7].  It is difficult to determine the true lineage of 
MPCs when these cells appear to undergo dramatic shifts in gene and protein 
expression in response to environmental cues.  For example, when removed from their 
niche in the bone marrow, putative MPCs are stimulated to rapidly divide, activating 
proliferation pathways.  By definition, a true stem cell should divide infrequently, 
suggesting that cultured MPCs again do not fit the description of a true stem cell, but 
may represent a transient amplifying descendant.   
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I have demonstrated a number of dynamic changes in cell surface molecules on 
equine bone marrow cells over time in culture.  My results suggest that cell surface 
proteins change in response to the culture environment.  For example, cells selected 
for CD14 cell surface protein at 2 days of culture appear to downregulate expression 
of this epitope over the next few weeks of culture.  CD14 expression is maintained at 
low levels in long term MPC cultures, suggesting that expression does eventually 
stabilize unless stimulated by another factor.  Stimulation with lipopolysaccharide 
(LPS) caused a significant upregulation in both CD14 gene and protein expression, 
demonstrating that MPCs can produce the LPS receptor, a cell surface protein 
specifically associated with hematopoietic cells.  Other hematopoietic specific cell 
surface proteins such as CD11a/CD18 are not expressed in bone marrow cells cultured 
more than two weeks.  However, it is still unclear if the protein is not present because 
the MPC population is truly non-hematopoietic in lineage, or if the expression of 
CD11a/CD18 has been downregulated as a response to extended culture.  Similarly to 
the previously described LPS stimulation test, CD11a/CD18 expression patterns in 
MPCs could be tested for gene and protein response in samples via intentional 
contamination with bacteria, or another known stimulant such as phorbol myristate 
acetate [8].  This test could help better define the lineage of MPCs as either 
hematopoietic or non-hematopoietic, as non-hematopoietic cells should not upregulate 
the specific hematopoietic protein CD11a/CD18. 
Further complicating the classification of putative MPCs is the lack of 
uniformity in cell surface protein expression in freshly isolated bone marrow cells.  I 
have demonstrated that freshly isolated bone marrow cells differ greatly in phenotype 
from bone marrow cells that have adhered two hours in culture.  Exploiting the 
difference in phenotype by selection of adherent cells for analysis may help to more 
clearly distinguish the cellular lineage of early equine MPCs.   
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Sample handling is another factor that can significantly alter the protein 
expression results of MPCs analyzed using flow cytometry.  A dramatic example of 
this effect was seen when trypsin was used for cell harvest prior to analysis.  The 
decreased mean fluorescence intensity detection of CD44, CD14, and CD172a 
proteins following trypsinization suggested these molecules were damaged by trypsin.  
Unfortunately, since the original description by Pittenger et al, many MPC 
characterization papers use trypsin as part of their protocols for adherent cell harvest 
prior to analysis by flow cytometry [9].  Although I have not tested the effect of 
trypsin in MPCs of other species, it is likely that damage to certain epitopes is not a 
phenomenon unique to the horse.  A study by Bryniarski et al. demonstrated that 
CD14 was trypsin labile in murine cells [10].  Further studies of MPCs in other 
species would be required, and would be of value to confirm whether damage to the 
cell surface proteins by trypsin could be a plausible explanation for the apparent 
discrepancy in MPC phenotype between horses and other species. 
 
What if Putative Equine MPCs are from a Hematopoietic Lineage?   
In theory, if putative MPCs are descendants of a hematopoietic lineage 
precursor, a hematopoietic specific antibody should be capable of enriching the MPC 
population.  Over the course of my research, I have discovered that positive selection 
using a mouse anti-equine CD14 antibody and magnetic activated cell sorting (MACS) 
on equine bone marrow cells cultured for 2 days resulted in an enrichment of MPC 
colony formation.  Only certain lineages of hematopoietic cells (e.g. monocytes, 
macrophages, dendritic cells, activated B lymphocytes and to a lesser extent 
neutrophils) are known to express CD14 protein on their cell surface.  The enrichment 
of MPC colonies in my study was unexpected based on the CD14 expression results 
reported in humans and other species for over a decade.  Based on previous 
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information, equine MPC colonies should have been concentrated in the CD14 
negative fraction.  Cultures of CD14 positively selected cells contained approximately 
double the number of MPC colonies compared to unsorted bone marrow cells and over 
twenty times the number of colonies in CD14 negatively selected cells at one week of 
culture.  Two possible interpretations of the dramatic concentration of MPC colony 
formation in the CD14 positive fraction include 1) MPCs truly lack CD14 expression 
and are merely using the CD14 positive cells for cell-cell signaling and stimulation of 
colony formation or 2) MPCs are derived from the CD14 positive fraction.  Although 
possible, the former possibility seems unlikely given the long term low levels of CD14 
gene and protein expression detected in cultured MPCs, the up regulation of CD14 
expression in MPCs in response to LPS stimulation, and the repeatability (with 
slightly less efficiency) of MPC colony formation results using a mouse anti-human 
CD14 antibody for sorting of equine bone marrow cells cultured 2 days (data not 
shown).  If the latter is the cause of MPC enrichment in the CD14 positive fraction, 
one of the main tenets of previous MPC studies (that MPCs are non-hematopoietic in 
lineage because they lack hematopoietic markers such as CD14) would need to be 
reevaluated.   A novel approach to further explore the question of whether MPCs are 
from a hematopoietic origin would be to use other hematopoietic markers, such as 
anti-equine CD11a/CD18 or MHC Class II antibodies, to sort bone marrow cells 
cultured 2 days and determine if MPC colony formation is also enriched in the 
positive fractions. 
 Ultimately, if putative MPCs are found to be of hematopoietic lineage, their 
reclassification will not only have an impact on nomenclature, but also on their 
clinical indications.  As will be discussed later in this chapter, if MPCs are 
descendants of a hematopoietic precursor, the therapeutic goal for their clinical use 
will need to shift from tissue regeneration to improved tissue repair and function; 
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however, before this is discussed, the current knowledge of MPC behavior in vivo 
needs to be summarized. 
 
Mesenchymal Progenitor Cell Behavior In Vivo  
To date, many studies have investigated the behavior of MPC in vivo.  
Although the initial goals of these studies were to demonstrate tissue regeneration as a 
direct result of MPC activity, most studies have concluded the main therapeutic effect 
of these cells is through secretion of trophic factors which modulate the immune 
response and regenerative microenvironment of the recipient [11-14]. 
“Differentiation” of MPCs into various mesenchymal tissues in vitro has not been 
repeatable following implantation of MPCs in vivo.  In fact, no study has been able to 
definitively demonstrate a tissue regenerative effect in vivo using MPCs to form the 
desired functional tissue.  However, a therapeutic effect from MPCs has been 
evaluated and observed in a variety of diseases including graft versus host diseases, 
bone disorders, myocardial infarcts, stroke, and spinal cord injuries [11].  Modulation 
of immune response and growth factor secretion during healing can improve clinical 
outcome and should be considered as valuable therapeutic effects of MPCs.    
In contrast, claiming “tissue regeneration” or “stem cell therapy” in unproven 
MPC applications might lead to confusion and false hopes and/or expectations for 
patients.  The potential augmentation of healing with use of MPCs in cell therapy 
could be disappointing to a patient who is expecting tissue regeneration.  Patients need 
to be informed of the potential benefits of MPC therapy, while also being educated to 
recognize the hype associated with “stem cell therapy”.  Providing realistic 
expectations of success to patients will vastly improve the credibility of MPC cell 
based therapies long term and promote continued evaluation of beneficial MPC 
properties in future studies. 
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Application of Findings to Future Equine MPC Studies and Clinical Relevance 
MPC-based therapies have been widely used in the horse to treat 
musculoskeletal conditions ranging from tendon, ligament, and cartilage defects that 
resulted from developmental abnormalities, traumatic lesions, and degenerative joint 
disease.  Commercial cell-based therapies have utilized cells isolated from various 
tissues including fat and bone marrow aspirate.  Cell processing techniques prior to 
implantation are also widely variable within the tissue source.  For example, cell grafts 
derived from bone marrow include whole bone marrow aspirate transplant, 
concentration of the mononuclear cell component of the bone marrow via 
centrifugation, and implantation of culture expanded putative MPCs.  While whole 
marrow injection requires no additional processing and can be performed patient-side, 
culture expansion of putative MPCs requires specialized equipment; facilities and 
many weeks between initial bone marrow aspirate harvest and graft implantation.  
Clinical results show some benefit in using cultured MPC cell-based grafts, however 
tissue regeneration does not occur [12].   
One major challenge to clinical application of these cells is striking the balance 
between implanting as many putative MPCs as possible while preventing “terminal 
differentiation” into a less plastic cell type over prolonged culture.  Reducing the time 
needed between cell harvest and implantation is an important of component of cell- 
based therapies in the horse.  Although putative MPCs derived from CD14 MACS 
sorting of bone marrow cells are by no means pure at two days of culture, the CD14 
positively selected fraction would be a good candidate to compare with other current 
cell-graft preparations in vivo.  At two days, cells which form MPC colonies have 
been concentrated to about 1 in 6,000 cells in the CD14 positively selected fraction.  
This can be compared to about 1 in 100,000 in uncultured bone marrow mononuclear 
cells.  CD14 positively selected cells at two days of culture should also be relatively 
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“plastic” compared to bone marrow cells cultured many weeks.  My results show no 
appreciable differences in long term expression of cell surface markers between MPCs 
derived from unsorted or MACS sorted cells, suggesting that the MPC colonies 
formed in each fraction have similar properties.  Therefore, the clinical benefit of 
using positively selected cells would be to generate a relatively high concentration of 
putative MPCs following a relatively short duration of culture.  
Ultimately, the search for the cell capable of mesenchymal tissue regeneration 
must continue.  A cell capable of mesenchymal tissue generation must certainly exist 
to allow for normal tissue turnover over the lifetime of the animal.  How can I 
distinguish the putative MPC population from the cell population which has true tissue 
regenerative capacity is a question that remains to be explored and answered. 
Techniques to promote in vivo mesenchymal differentiation via cells with induced 
pluripotency or embryonic stem cells induced down a mesenchymal differentiation 
pathway will likely be the most promising sources of truly regenerative mesenchymal 
cells.  However, further work to exploit the therapeutic benefits of adult derived cells 
can be useful, and should not be overlooked as indications for clinical applications.  
Clearly many questions remain in the relatively poorly understood field of equine 
MPC biology.   
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APPENDIX 
List of relevant CD antigens 
 
CD antigen  Alternate name(s)  Distribution 
CD3   CD3γ    T, Thymocyte 
CD11a   LFA-1, integrin αL  lymph, gran, mono, mac 
CD11b                         Mac-1, integrin αM   myeloid cells, NK 
CD13                          Aminopeptidase N   myeloid cells 
CD14                           LPS-R   Mono, mac, Langer, gran (low) 
CD18                          integrin β2   hema 
CD19                           B4    B, FDC 
CD29                           platelet GP11A, integrin β1 Hema, endo, fibro, mast 
CD34                           My10, Mucosialin   Hema prec, endo, embryonic fibro 
CD44                           H-CAM, Pgp-1   Hema and non-hema except plat 
CD45                           LCA, PTPRC, B220  Hema (multiple isoforms) 
CD45RB                     LCA   B, T, mono, mac, gran 
CD79alpha                  Iga, MB-1   B 
CD90                          Thy-1   CD34+ hema sub, neurons, gran 
CD105                        Endoglin, SH2   Endo, bone marrow sub, activated   
       mono/mac 
CD172a  SIRPα    mono, T, stem cells 
 
Endo  endothelial cells  NK  natural killer cells 
FDC  follicular dendritic cells Mac  macrophages 
Fibro  fibroblasts   mono  monocytes 
Gran  granulocytes   plat  platelets 
Hema  hematopoietic cells  prec  precursors 
Langer  Langerhans cells  sub  sub-set 
Lymph  lymphocytes 
